
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pulse</journal-id><journal-id journal-id-type="iso-abbrev">Pulse</journal-id><journal-id journal-id-type="publisher-id">PLS</journal-id><journal-title-group><journal-title>Pulse</journal-title></journal-title-group><issn pub-type="ppub">2235-8676</issn><issn pub-type="epub">2235-8668</issn><publisher><publisher-name>S. Karger AG</publisher-name><publisher-loc>Allschwilerstrasse 10, P.O. Box &#x000b7; Postfach &#x000b7; Case postale, CH&#x02013;4009, Basel, Switzerland &#x000b7; Schweiz &#x000b7; Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.ch</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26587429</article-id><article-id pub-id-type="pmc">4315340</article-id><article-id pub-id-type="doi">10.1159/000354108</article-id><article-id pub-id-type="publisher-id">pls-0001-0097</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Effects of Various Antihypertensive Drugs on Arterial Stiffness and Wave Reflections</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Ming</given-names></name></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Ge-Le</given-names></name></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yan</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Ji-Guang</given-names></name><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff>Centre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China</aff><author-notes><corresp id="cor1">*Ji-Guang Wang, MD, PhD, The Shanghai Institute of Hypertension, Ruijin 2nd Road 197, Shanghai 200025 (China), E-Mail <email>jiguangwang@aim.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>10</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>10</day><month>9</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>9</month><year>2013</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. --><volume>1</volume><issue>2</issue><fpage>97</fpage><lpage>107</lpage><permissions><copyright-statement>Copyright &#x000a9; 2013 by S. Karger AG, Basel</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://www.karger.com/Authors_Choice"><license-p>This is an open access article distributed under the terms of Karger's Author's Choice&#x02122; licensing agreement, adapted from the Creative Commons Attribution Non-Commercial 2.5 license. This license allows authors to re-use their articles for educational and research purposes as long as the author and the journal are fully acknowledged.</license-p></license></permissions><abstract><p>We reviewed trials that tested the efficacy of antihypertensive drugs in reducing arterial stiffness and wave reflections as assessed by pulse wave velocity and augmentation index, respectively. Regardless of cross-over or parallel-group comparison design, placebo-controlled trials demonstrated that antihypertensive drugs were effective in reducing pulse wave velocity. In actively-controlled parallel-group comparison studies, this effect on arterial stiffness was more evident for angiotensin-converting enzyme inhibitors or angiotensin receptor blockers than other classes of antihypertensive drugs, particularly when brachial-ankle pulse wave velocity was measured. Regardless of cross-over or parallel-group comparison or placebo- or actively-controlled design, the reviewed trials showed that &#x003b2;-blockers were inferior to all the other classes of antihypertensive drugs in reducing augmentation index. However, these studies had a small sample size and a short follow-up time and did not link the changes in measurements of arterial function with cardiovascular events. Whether the superiority or inferiority is clinically relevant for cardiovascular protection and prevention remains to be investigated.</p></abstract><kwd-group><title>Key Words</title><kwd>Antihypertensive drugs</kwd><kwd>Arterial stiffness</kwd><kwd>Wave reflections</kwd><kwd>Randomized controlled trial</kwd></kwd-group><counts><table-count count="4"/><ref-count count="66"/><page-count count="11"/></counts></article-meta></front><body><sec sec-type="intro" id="sec1_1"><title>Introduction</title><p>In the past 2 decades, noninvasive measurements of arterial function are increasingly used as an intermediate measure of cardiovascular disease risk in therapeutic trials, such as antihypertensive therapy. Among various parameters of arterial function, pulse wave velocity and augmentation index measure arterial stiffness and wave reflections, respectively. Both measures can be accurately estimated within minutes with easy-to-use devices and may predict cardiovascular events above and beyond conventional cardiovascular risk factors, such as high blood pressure [<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>]. However, at present, there is no specific treatment for increased arterial stiffness or wave reflections. Nonetheless, antihypertensive drugs, especially those of vasodilatating action, seem to be promising in this regard.</p><p>Since the early 1990s, several randomized controlled trials have been conducted to study the effects of various antihypertensive drugs on carotid-femoral or brachial-ankle pulse wave velocity and augmentation index. In the present review article, we summarized these trials to investigate whether and which antihypertensive drugs are efficacious in reducing arterial stiffness and wave reflections and to explore the clinical relevance of these arterial measurements for cardiovascular protection and prevention.</p></sec><sec id="sec1_2"><title>Arterial Effects of Antihypertensive Drugs in Placebo-Controlled Trials</title><p>Of the 27 placebo-controlled trials, 11 had a cross-over design (table <xref ref-type="table" rid="T1">1</xref>) [<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>] and 16 had a parallel-group comparison design (table <xref ref-type="table" rid="T2">2</xref>) [<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B21" ref-type="bibr">21</xref>,<xref rid="B22" ref-type="bibr">22</xref>,<xref rid="B23" ref-type="bibr">23</xref>,<xref rid="B24" ref-type="bibr">24</xref>,<xref rid="B25" ref-type="bibr">25</xref>,<xref rid="B26" ref-type="bibr">26</xref>,<xref rid="B27" ref-type="bibr">27</xref>,<xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B29" ref-type="bibr">29</xref>]. Regardless of the design, these placebo-controlled studies had a sample size of tens and a follow-up time of weeks.</p><p>Of the 11 placebo-controlled cross-over trials, 6 and 5 had single [<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>] and multiple comparisons with placebo [<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B7" ref-type="bibr">7</xref>], respectively, and 2, 4, and 5 studied pulse wave velocity [<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B13" ref-type="bibr">13</xref>], augmentation index alone [<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B10" ref-type="bibr">10</xref>], and both [<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B12" ref-type="bibr">12</xref>], respectively (table <xref ref-type="table" rid="T1">1</xref>). The results of these trials were generally consistent across various classes of antihypertensive drugs for pulse wave velocity but not augmentation index. Antihypertensive drugs were efficacious in reducing pulse wave velocity. However, most drugs had neutral effects on augmentation index, and &#x003b2;-blockers even had worse effects than placebo on this measure of wave reflections [<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B12" ref-type="bibr">12</xref>].</p><p>Of the 16 placebo-controlled parallel-group comparison trials, 12 and 4 had single [<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B21" ref-type="bibr">21</xref>,<xref rid="B22" ref-type="bibr">22</xref>,<xref rid="B24" ref-type="bibr">24</xref>,<xref rid="B25" ref-type="bibr">25</xref>,<xref rid="B27" ref-type="bibr">27</xref>,<xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B29" ref-type="bibr">29</xref>] and multiple comparisons with placebo [<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B23" ref-type="bibr">23</xref>,<xref rid="B26" ref-type="bibr">26</xref>], respectively, and 8, 3, and 5 studied pulse wave velocity [<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B24" ref-type="bibr">24</xref>,<xref rid="B25" ref-type="bibr">25</xref>,<xref rid="B26" ref-type="bibr">26</xref>,<xref rid="B27" ref-type="bibr">27</xref>,<xref rid="B28" ref-type="bibr">28</xref>], augmentation index alone [<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B23" ref-type="bibr">23</xref>], and both [<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B21" ref-type="bibr">21</xref>,<xref rid="B22" ref-type="bibr">22</xref>,<xref rid="B29" ref-type="bibr">29</xref>], respectively (table <xref ref-type="table" rid="T2">2</xref>). The results of these parallel-group comparison trials were confirmatory for pulse wave velocity. Antihypertensive drugs significantly reduced pulse wave velocity in 10 of 18 drug comparisons from 13 trials. However, the results of these trials were slightly different for augmentation index. Antihypertensive drugs significantly reduced pulse wave velocity in 4 of 10 drug comparisons from 8 trials, none of which used &#x003b2;-blockers.</p></sec><sec id="sec1_3"><title>Arterial Effects of Antihypertensive Drugs in Actively-Controlled Trials</title><p>The actively-controlled trials also included those studies involving 2 or more drug comparisons with placebo. Of the 15 trials with a cross-over design (table <xref ref-type="table" rid="T3">3</xref>) [<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B30" ref-type="bibr">30</xref>,<xref rid="B31" ref-type="bibr">31</xref>,<xref rid="B32" ref-type="bibr">32</xref>,<xref rid="B33" ref-type="bibr">33</xref>,<xref rid="B34" ref-type="bibr">34</xref>,<xref rid="B35" ref-type="bibr">35</xref>,<xref rid="B36" ref-type="bibr">36</xref>,<xref rid="B37" ref-type="bibr">37</xref>,<xref rid="B38" ref-type="bibr">38</xref>] and 31 trials with a parallel-group comparison design (table <xref ref-type="table" rid="T4">4</xref>) [<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B23" ref-type="bibr">23</xref>,<xref rid="B26" ref-type="bibr">26</xref>,<xref rid="B39" ref-type="bibr">39</xref>,<xref rid="B40" ref-type="bibr">40</xref>,<xref rid="B41" ref-type="bibr">41</xref>,<xref rid="B42" ref-type="bibr">42</xref>,<xref rid="B43" ref-type="bibr">43</xref>,<xref rid="B44" ref-type="bibr">44</xref>,<xref rid="B45" ref-type="bibr">45</xref>,<xref rid="B46" ref-type="bibr">46</xref>,<xref rid="B47" ref-type="bibr">47</xref>,<xref rid="B48" ref-type="bibr">48</xref>,<xref rid="B49" ref-type="bibr">49</xref>,<xref rid="B50" ref-type="bibr">50</xref>,<xref rid="B51" ref-type="bibr">51</xref>,<xref rid="B52" ref-type="bibr">52</xref>,<xref rid="B53" ref-type="bibr">53</xref>,<xref rid="B54" ref-type="bibr">54</xref>,<xref rid="B55" ref-type="bibr">55</xref>,<xref rid="B56" ref-type="bibr">56</xref>,<xref rid="B57" ref-type="bibr">57</xref>,<xref rid="B58" ref-type="bibr">58</xref>,<xref rid="B59" ref-type="bibr">59</xref>,<xref rid="B60" ref-type="bibr">60</xref>,<xref rid="B61" ref-type="bibr">61</xref>,<xref rid="B62" ref-type="bibr">62</xref>,<xref rid="B63" ref-type="bibr">63</xref>,<xref rid="B64" ref-type="bibr">64</xref>,<xref rid="B65" ref-type="bibr">65</xref>], 6 [<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B10" ref-type="bibr">10</xref>] and 4 [<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B23" ref-type="bibr">23</xref>,<xref rid="B26" ref-type="bibr">26</xref>], respectively, were part of placebo-controlled studies. These actively-controlled studies also had a small sample size and short follow-up time with the exception of the CAFE (n = 2,073) [<xref rid="B61" ref-type="bibr">61</xref>], EXPLORE (n = 331) [<xref rid="B50" ref-type="bibr">50</xref>], and REASON trials (n = 406) [<xref rid="B65" ref-type="bibr">65</xref>]. These bigger studies investigated combination therapy and (except REASON [<xref rid="B65" ref-type="bibr">65</xref>]) had an open design, and hence had limited information on the comparison between drug classes.</p><p>Of the cross-over trials, 2, 7, and 6 studied pulse wave velocity [<xref rid="B31" ref-type="bibr">31</xref>,<xref rid="B37" ref-type="bibr">37</xref>], augmentation index alone [<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B32" ref-type="bibr">32</xref>,<xref rid="B33" ref-type="bibr">33</xref>,<xref rid="B36" ref-type="bibr">36</xref>,<xref rid="B38" ref-type="bibr">38</xref>], and both [<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B30" ref-type="bibr">30</xref>,<xref rid="B34" ref-type="bibr">34</xref>,<xref rid="B35" ref-type="bibr">35</xref>], respectively (table <xref ref-type="table" rid="T3">3</xref>). These trials included 15 comparisons of angiotensin-converting enzyme (ACE) inhibitors with angiotensin receptor blockers (ARBs; n = 3) [<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B30" ref-type="bibr">30</xref>,<xref rid="B31" ref-type="bibr">31</xref>], &#x003b2;-blockers (n = 7) [<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B32" ref-type="bibr">32</xref>,<xref rid="B33" ref-type="bibr">33</xref>,<xref rid="B34" ref-type="bibr">34</xref>], calcium channel blockers (CCBs; n = 3) [<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B33" ref-type="bibr">33</xref>], and diuretics (n = 2) [<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>], 2 comparisons of ARBs with &#x003b2;-blockers [<xref rid="B35" ref-type="bibr">35</xref>,<xref rid="B36" ref-type="bibr">36</xref>], 6 comparisons between 2 different &#x003b2;-blockers (n = 1) [<xref rid="B10" ref-type="bibr">10</xref>] or of &#x003b2;-blockers with CCBs (n = 3) [<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B33" ref-type="bibr">33</xref>] and diuretics (n = 2) [<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>], 3 comparisons of CCBs with diuretics [<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B37" ref-type="bibr">37</xref>], and 2 comparisons of combination therapy with each of their component drugs [<xref rid="B30" ref-type="bibr">30</xref>,<xref rid="B38" ref-type="bibr">38</xref>]. In these short-term cross-over studies, antihypertensive drugs had similar arterial effects, except that &#x003b2;-blockers were inferior to the other classes of antihypertensive drugs in reducing augmentation index in 11 of 14 comparisons with ACE inhibitors, ARBs, CCBs, or diuretics.</p><p>Of the parallel group trials, 20, 4, and 7 studied pulse wave velocity [<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B26" ref-type="bibr">26</xref>,<xref rid="B39" ref-type="bibr">39</xref>,<xref rid="B40" ref-type="bibr">40</xref>,<xref rid="B41" ref-type="bibr">41</xref>,<xref rid="B42" ref-type="bibr">42</xref>,<xref rid="B43" ref-type="bibr">43</xref>,<xref rid="B46" ref-type="bibr">46</xref>,<xref rid="B47" ref-type="bibr">47</xref>,<xref rid="B49" ref-type="bibr">49</xref>,<xref rid="B52" ref-type="bibr">52</xref>,<xref rid="B53" ref-type="bibr">53</xref>,<xref rid="B54" ref-type="bibr">54</xref>,<xref rid="B55" ref-type="bibr">55</xref>,<xref rid="B56" ref-type="bibr">56</xref>,<xref rid="B58" ref-type="bibr">58</xref>,<xref rid="B59" ref-type="bibr">59</xref>,<xref rid="B60" ref-type="bibr">60</xref>,<xref rid="B62" ref-type="bibr">62</xref>], augmentation index alone [<xref rid="B23" ref-type="bibr">23</xref>,<xref rid="B48" ref-type="bibr">48</xref>,<xref rid="B57" ref-type="bibr">57</xref>,<xref rid="B63" ref-type="bibr">63</xref>], and both [<xref rid="B44" ref-type="bibr">44</xref>,<xref rid="B45" ref-type="bibr">45</xref>,<xref rid="B50" ref-type="bibr">50</xref>,<xref rid="B51" ref-type="bibr">51</xref>,<xref rid="B61" ref-type="bibr">61</xref>,<xref rid="B64" ref-type="bibr">64</xref>,<xref rid="B65" ref-type="bibr">65</xref>], respectively (table <xref ref-type="table" rid="T4">4</xref>). These trials included 20 comparisons of ACE inhibitors with ARBs (n = 6) [<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B39" ref-type="bibr">39</xref>,<xref rid="B40" ref-type="bibr">40</xref>,<xref rid="B41" ref-type="bibr">41</xref>,<xref rid="B42" ref-type="bibr">42</xref>,<xref rid="B43" ref-type="bibr">43</xref>], &#x003b2;-blockers (n = 2) [<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B44" ref-type="bibr">44</xref>], CCBs (n = 8) [<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B39" ref-type="bibr">39</xref>,<xref rid="B40" ref-type="bibr">40</xref>,<xref rid="B43" ref-type="bibr">43</xref>,<xref rid="B44" ref-type="bibr">44</xref>,<xref rid="B45" ref-type="bibr">45</xref>,<xref rid="B46" ref-type="bibr">46</xref>], and diuretics (n = 4) [<xref rid="B44" ref-type="bibr">44</xref>,<xref rid="B47" ref-type="bibr">47</xref>,<xref rid="B48" ref-type="bibr">48</xref>,<xref rid="B49" ref-type="bibr">49</xref>], 13 comparisons of ARBs with &#x003b2;-blockers (n = 2) [<xref rid="B50" ref-type="bibr">50</xref>,<xref rid="B51" ref-type="bibr">51</xref>], CCBs (n = 10) [<xref rid="B39" ref-type="bibr">39</xref>,<xref rid="B40" ref-type="bibr">40</xref>,<xref rid="B43" ref-type="bibr">43</xref>,<xref rid="B52" ref-type="bibr">52</xref>,<xref rid="B53" ref-type="bibr">53</xref>,<xref rid="B54" ref-type="bibr">54</xref>,<xref rid="B55" ref-type="bibr">55</xref>,<xref rid="B56" ref-type="bibr">56</xref>,<xref rid="B57" ref-type="bibr">57</xref>,<xref rid="B58" ref-type="bibr">58</xref>], or a diuretic (n = 1) [<xref rid="B23" ref-type="bibr">23</xref>], 5 comparisons of &#x003b2;-blockers with CCBs (n = 4) [<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B26" ref-type="bibr">26</xref>,<xref rid="B44" ref-type="bibr">44</xref>,<xref rid="B59" ref-type="bibr">59</xref>] or a diuretic (n = 1) [<xref rid="B44" ref-type="bibr">44</xref>], 7 comparisons between 2 different CCBs (n = 1) [<xref rid="B40" ref-type="bibr">40</xref>] or of CCBs with diuretics (n = 6) [<xref rid="B44" ref-type="bibr">44</xref>,<xref rid="B60" ref-type="bibr">60</xref>,<xref rid="B61" ref-type="bibr">61</xref>,<xref rid="B62" ref-type="bibr">62</xref>,<xref rid="B63" ref-type="bibr">63</xref>,<xref rid="B64" ref-type="bibr">64</xref>], and 2 comparisons of combination therapy with one [<xref rid="B65" ref-type="bibr">65</xref>] or two of their component drugs [<xref rid="B41" ref-type="bibr">41</xref>]. In these studies, ACE inhibitors or ARBs tended to be more efficacious than other classes of antihypertensive drugs in reducing arterial stiffness, especially when brachial-ankle pulse wave velocity was measured in 11 trials [<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B40" ref-type="bibr">40</xref>,<xref rid="B41" ref-type="bibr">41</xref>,<xref rid="B43" ref-type="bibr">43</xref>,<xref rid="B46" ref-type="bibr">46</xref>,<xref rid="B52" ref-type="bibr">52</xref>,<xref rid="B53" ref-type="bibr">53</xref>,<xref rid="B54" ref-type="bibr">54</xref>,<xref rid="B56" ref-type="bibr">56</xref>,<xref rid="B58" ref-type="bibr">58</xref>,<xref rid="B62" ref-type="bibr">62</xref>]. The results were not consistent for other comparisons of pulse wave velocity or for studies on augmentation index, except that &#x003b2;-blockers were inferior to the other classes of antihypertensive drugs in reducing augmentation index in all 5 comparisons with an ACE inhibitor (n = 1) [<xref rid="B44" ref-type="bibr">44</xref>], ARBs (n = 2) [<xref rid="B50" ref-type="bibr">50</xref>,<xref rid="B51" ref-type="bibr">51</xref>], a CCB (n = 1) [<xref rid="B44" ref-type="bibr">44</xref>], or a diuretic (n = 1) [<xref rid="B44" ref-type="bibr">44</xref>].</p></sec><sec id="sec1_4"><title>Conclusions and Perspectives</title><p>Our narrative review was informative on three clinically relevant questions. First, antihypertensive drugs are effective in reducing arterial stiffness. However, this effect does not at all infer any benefit above and beyond blood pressure lowering. In contrast, because pulse wave velocity is dependent on systolic blood pressure, the therapeutic effect of antihypertensive drugs on arterial stiffness, to some extent if not entirely, can be attributable to their blood pressure lowering efficacy. Second, though all antihypertensive drugs reduce arterial stiffness, ACE inhibitors or ARBs might be more efficacious than other classes of antihypertensive drugs. This effect is more evident when brachial-ankle pulse wave velocity is measured. The mechanism remains to be elucidated. Third, as also evidenced by a recent meta-analysis of randomized controlled trials that compared &#x003b2;-blockers with the other classes of antihypertensive drugs [<xref rid="B66" ref-type="bibr">66</xref>], because of the intrinsic heart rate slowing effect, &#x003b2;-blockers are inferior to all the other classes of antihypertensive drugs in reducing augmentation index. However, whether this inferiority is clinically relevant for cardiovascular protection and prevention remains to be investigated.</p><p>In spite of a large number of trials that studied the efficacy of antihypertensive drugs in reducing pulse wave velocity and augmentation index, these studies had a small sample size and a short follow-up time and did not link the changes in measurements of arterial function with cardiovascular events. It is therefore imperative to combine the research force in the field of arterial functions to run adequately powered outcome trials to investigate whether arterial stiffness and wave reflections are clinically useful in monitoring the effect of antihypertensive treatment and other cardiovascular therapeutic approaches.</p></sec><sec id="sec1_5"><title>Disclosure Statement</title><p>J.-G.W. reports receiving lecture and consulting fees from A&#x00026;D, Boehringer-Ingelheim, MSD, Novartis, Omron, Pfizer, Servier, and Takeda.</p></sec></body><back><ack><title>Acknowledgement</title><p>The authors were financially supported by grants from the National Natural Science Foundation of China (grants 30871360, 30871081, 81170245, and 81270373), the Ministry of Science and Technology (a grant for China-European Union collaborations, 1012), and the Ministry of Education (NCET-09-0544), Beijing, China, the Shanghai Commissions of Science and Technology (grant 07JC14047, the &#x02018;Rising Star' program 06QA14043, and 11QH1402000) and Education (grant 07ZZ32 and the &#x02018;Dawn' project 08SG20), the Shanghai Bureau of Health (XBR2011004), Shanghai Jiaotong University School of Medicine (a grant of Distinguished Young Investigators to Y.L.), and the European Union (grants LSHM-CT-2006-037093 and HEALTH-F4-2007-201550).</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vlachopoulos</surname><given-names>C</given-names></name><name><surname>Aznaouridis</surname><given-names>K</given-names></name><name><surname>Stefanadis</surname><given-names>C</given-names></name></person-group><article-title>Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis</article-title><source>J Am Coll Cardiol</source><year>2010</year><volume>55</volume><fpage>1318</fpage><lpage>1327</lpage><pub-id pub-id-type="pmid">20338492</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vlachopoulos</surname><given-names>C</given-names></name><name><surname>Aznaouridis</surname><given-names>K</given-names></name><name><surname>O'Rourke</surname><given-names>MF</given-names></name><name><surname>Safar</surname><given-names>ME</given-names></name><name><surname>Baou</surname><given-names>K</given-names></name><name><surname>Stefanadis</surname><given-names>C</given-names></name></person-group><article-title>Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis</article-title><source>Eur Heart J</source><year>2010</year><volume>31</volume><fpage>1865</fpage><lpage>1871</lpage><pub-id pub-id-type="pmid">20197424</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pannier</surname><given-names>BM</given-names></name><name><surname>Guerin</surname><given-names>AP</given-names></name><name><surname>Marchais</surname><given-names>SJ</given-names></name><name><surname>London</surname><given-names>GM</given-names></name></person-group><article-title>Different aortic reflection wave responses following long-term angiotensin-converting enzyme inhibition and beta-blocker in essential hypertension</article-title><source>Clin Exp Pharmacol Physiol</source><year>2001</year><volume>28</volume><fpage>1074</fpage><lpage>1077</lpage><pub-id pub-id-type="pmid">11903319</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deary</surname><given-names>AJ</given-names></name><name><surname>Schumann</surname><given-names>AL</given-names></name><name><surname>Murfet</surname><given-names>H</given-names></name><name><surname>Haydock</surname><given-names>S</given-names></name><name><surname>Foo</surname><given-names>RS</given-names></name><name><surname>Brown</surname><given-names>MJ</given-names></name></person-group><article-title>Influence of drugs and gender on the arterial pulse wave and natriuretic peptide secretion in untreated patients with essential hypertension</article-title><source>Clin Sci (Lond)</source><year>2002</year><volume>103</volume><fpage>493</fpage><lpage>499</lpage><pub-id pub-id-type="pmid">12401122</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>T</given-names></name><name><surname>Lauri</surname><given-names>J</given-names></name><name><surname>Bertram</surname><given-names>D</given-names></name><name><surname>Anderson</surname><given-names>A</given-names></name></person-group><article-title>Effect of different antihypertensive drug classes on central aortic pressure</article-title><source>Am J Hypertens</source><year>2004</year><volume>17</volume><fpage>118</fpage><lpage>123</lpage><pub-id pub-id-type="pmid">14751652</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirata</surname><given-names>K</given-names></name><name><surname>Vlachopoulos</surname><given-names>C</given-names></name><name><surname>Adji</surname><given-names>A</given-names></name><name><surname>O'Rourke</surname><given-names>MF</given-names></name></person-group><article-title>Benefits from angiotensin-converting enzyme inhibitor &#x02018;beyond blood pressure lowering&#x02019;: beyond blood pressure or beyond the brachial artery?</article-title><source>J Hypertens</source><year>2005</year><volume>23</volume><fpage>551</fpage><lpage>556</lpage><pub-id pub-id-type="pmid">15716696</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>CL</given-names></name><name><surname>Wilkinson</surname><given-names>IB</given-names></name><name><surname>Kirkpatrick</surname><given-names>PJ</given-names></name></person-group><article-title>Use of antihypertension agents for the suppression of arterial pulse pressure waveforms in patients with intracranial aneurysms</article-title><source>J Neurosurg</source><year>2006</year><volume>104</volume><fpage>531</fpage><lpage>536</lpage><pub-id pub-id-type="pmid">16619656</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asmar</surname><given-names>R</given-names></name><name><surname>Gosse</surname><given-names>P</given-names></name><name><surname>Topouchian</surname><given-names>J</given-names></name><name><surname>N'Tela</surname><given-names>G</given-names></name><name><surname>Dudley</surname><given-names>A</given-names></name><name><surname>Shepherd</surname><given-names>GL</given-names></name></person-group><article-title>Effects of telmisartan on arterial stiffness in type 2 diabetes patients with essential hypertension</article-title><source>J Renin Angiotensin Aldosterone Syst</source><year>2002</year><volume>3</volume><fpage>176</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">12563568</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajagopalan</surname><given-names>S</given-names></name><name><surname>Kariisa</surname><given-names>M</given-names></name><name><surname>Dellegrottaglie</surname><given-names>S</given-names></name><name><surname>Bard</surname><given-names>RL</given-names></name><name><surname>Kehrer</surname><given-names>C</given-names></name><name><surname>Matlow</surname><given-names>S</given-names></name><name><surname>Daley</surname><given-names>W</given-names></name><name><surname>Pitt</surname><given-names>B</given-names></name><name><surname>Brook</surname><given-names>R</given-names></name></person-group><article-title>Angiotensin receptor blockade improves vascular compliance in healthy normotensive elderly individuals: results from a randomized double-blind placebo-controlled trial</article-title><source>J Clin Hypertens (Greenwich)</source><year>2006</year><volume>8</volume><fpage>783</fpage><lpage>790</lpage><pub-id pub-id-type="pmid">17086018</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufman</surname><given-names>R</given-names></name><name><surname>Nunes</surname><given-names>I</given-names></name><name><surname>Bolognese</surname><given-names>JA</given-names></name><name><surname>Miller</surname><given-names>DL</given-names></name><name><surname>Salotti</surname><given-names>D</given-names></name><name><surname>McCarthy</surname><given-names>JM</given-names></name><name><surname>Smith</surname><given-names>WB</given-names></name><name><surname>Herman</surname><given-names>GA</given-names></name><name><surname>Feig</surname><given-names>PU</given-names></name></person-group><article-title>Single-dose effects of isosorbidemononitrate alone or in combination with losartan on central blood pressure</article-title><source>J Am Soc Hypertens</source><year>2010</year><volume>4</volume><fpage>311</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">21130977</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asmar</surname><given-names>RG</given-names></name><name><surname>Kerihuel</surname><given-names>JC</given-names></name><name><surname>Girerd</surname><given-names>XJ</given-names></name><name><surname>Safar</surname><given-names>ME</given-names></name></person-group><article-title>Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension</article-title><source>Am J Cardiol</source><year>1991</year><volume>68</volume><fpage>61</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">1676238</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhakam</surname><given-names>Z</given-names></name><name><surname>Yasmin, McEniery</surname><given-names>CM</given-names></name><name><surname>Burton</surname><given-names>T</given-names></name><name><surname>Brown</surname><given-names>MJ</given-names></name><name><surname>Wilkinson</surname><given-names>IB</given-names></name></person-group><article-title>A comparison of atenolol and nebivolol in isolated systolic hypertension</article-title><source>J Hypertens</source><year>2008</year><volume>26</volume><fpage>351</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">18192850</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>J</given-names></name><name><surname>Gavin</surname><given-names>A</given-names></name><name><surname>Band</surname><given-names>M</given-names></name><name><surname>Morris</surname><given-names>A</given-names></name><name><surname>Struthers</surname><given-names>A</given-names></name></person-group><article-title>Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients</article-title><source>Br J Clin Pharmacol</source><year>2005</year><volume>59</volume><fpage>520</fpage><lpage>523</lpage><pub-id pub-id-type="pmid">15842549</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahonen</surname><given-names>M</given-names></name><name><surname>Ylitalo</surname><given-names>R</given-names></name><name><surname>Koobi</surname><given-names>T</given-names></name><name><surname>Turjanmaa</surname><given-names>V</given-names></name><name><surname>Ylitalo</surname><given-names>P</given-names></name></person-group><article-title>Influence of captopril, propranolol, and verapamil on arterial pulse wave velocity and other cardiovascular parameters in healthy volunteers</article-title><source>Int J Clin Pharmacol Ther</source><year>1998</year><volume>36</volume><fpage>483</fpage><lpage>489</lpage><pub-id pub-id-type="pmid">9760009</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dart</surname><given-names>AM</given-names></name><name><surname>Reid</surname><given-names>CM</given-names></name><name><surname>McGrath</surname><given-names>B</given-names></name></person-group><article-title>Effects of ACE inhibitor therapy on derived central arterial waveforms in hypertension</article-title><source>Am J Hypertens</source><year>2001</year><volume>14</volume><fpage>804</fpage><lpage>810</lpage><pub-id pub-id-type="pmid">11497198</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ichihara</surname><given-names>A</given-names></name><name><surname>Hayashi</surname><given-names>M</given-names></name><name><surname>Kaneshiro</surname><given-names>Y</given-names></name><name><surname>Takemitsu</surname><given-names>T</given-names></name><name><surname>Homma</surname><given-names>K</given-names></name><name><surname>Kanno</surname><given-names>Y</given-names></name><name><surname>Yoshizawa</surname><given-names>M</given-names></name><name><surname>Furukawa</surname><given-names>T</given-names></name><name><surname>Takenaka</surname><given-names>T</given-names></name><name><surname>Saruta</surname><given-names>T</given-names></name></person-group><article-title>Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients</article-title><source>Am J Kidney Dis</source><year>2005</year><volume>45</volume><fpage>866</fpage><lpage>874</lpage><pub-id pub-id-type="pmid">15861352</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>WC</given-names></name><name><surname>Lin</surname><given-names>YP</given-names></name><name><surname>Lin</surname><given-names>IF</given-names></name><name><surname>Chuang</surname><given-names>SY</given-names></name><name><surname>Chen</surname><given-names>CH</given-names></name></person-group><article-title>Effect of ramipril on left ventricular mass in normotensive hemodialysis patients</article-title><source>Am J Kidney Dis</source><year>2006</year><volume>47</volume><fpage>478</fpage><lpage>484</lpage><pub-id pub-id-type="pmid">16490627</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsang</surname><given-names>TS</given-names></name><name><surname>Barnes</surname><given-names>ME</given-names></name><name><surname>Abhayaratna</surname><given-names>WP</given-names></name><name><surname>Cha</surname><given-names>SS</given-names></name><name><surname>Gersh</surname><given-names>BJ</given-names></name><name><surname>Langins</surname><given-names>AP</given-names></name><name><surname>Green</surname><given-names>TD</given-names></name><name><surname>Bailey</surname><given-names>KR</given-names></name><name><surname>Miyasaka</surname><given-names>Y</given-names></name><name><surname>Seward</surname><given-names>JB</given-names></name></person-group><article-title>Effects of quinapril on left atrial structural remodeling and arterial stiffness</article-title><source>Am J Cardiol</source><year>2006</year><volume>97</volume><fpage>916</fpage><lpage>920</lpage><pub-id pub-id-type="pmid">16516602</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahimastos</surname><given-names>AA</given-names></name><name><surname>Aggarwal</surname><given-names>A</given-names></name><name><surname>D'Orsa</surname><given-names>KM</given-names></name><name><surname>Formosa</surname><given-names>MF</given-names></name><name><surname>White</surname><given-names>AJ</given-names></name><name><surname>Savarirayan</surname><given-names>R</given-names></name><name><surname>Dart</surname><given-names>AM</given-names></name><name><surname>Kingwell</surname><given-names>BA</given-names></name></person-group><article-title>Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial</article-title><source>JAMA</source><year>2007</year><volume>298</volume><fpage>1539</fpage><lpage>1547</lpage><pub-id pub-id-type="pmid">17911499</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname><given-names>S</given-names></name><name><surname>Ismail</surname><given-names>AA</given-names></name><name><surname>Ismail</surname><given-names>SB</given-names></name><name><surname>Naing</surname><given-names>NN</given-names></name><name><surname>Abdul</surname><given-names>RA</given-names></name></person-group><article-title>Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled study</article-title><source>Eur J Clin Pharmacol</source><year>2007</year><volume>63</volume><fpage>733</fpage><lpage>741</lpage><pub-id pub-id-type="pmid">17565489</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>GF</given-names></name><name><surname>Dunlap</surname><given-names>ME</given-names></name><name><surname>Warnica</surname><given-names>W</given-names></name><name><surname>Ducharme</surname><given-names>A</given-names></name><name><surname>Arnold</surname><given-names>JM</given-names></name><name><surname>Tardif</surname><given-names>JC</given-names></name><name><surname>Solomon</surname><given-names>SD</given-names></name><name><surname>Domanski</surname><given-names>MJ</given-names></name><name><surname>Jablonski</surname><given-names>KA</given-names></name><name><surname>Rice</surname><given-names>MM</given-names></name><name><surname>Pfeffer</surname><given-names>MA</given-names></name></person-group><article-title>MA: Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy</article-title><source>Hypertension</source><year>2007</year><volume>49</volume><fpage>1271</fpage><lpage>1277</lpage><pub-id pub-id-type="pmid">17452505</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahimastos</surname><given-names>AA</given-names></name><name><surname>Dart</surname><given-names>AM</given-names></name><name><surname>Lawler</surname><given-names>A</given-names></name><name><surname>Blombery</surname><given-names>PA</given-names></name><name><surname>Kingwell</surname><given-names>BA</given-names></name></person-group><article-title>Reduced arterial stiffness may contribute to angiotensin-converting enzyme inhibitor induced improvements in walking time in peripheral arterial disease patients</article-title><source>J Hypertens</source><year>2008</year><volume>26</volume><fpage>1037</fpage><lpage>1042</lpage><pub-id pub-id-type="pmid">18398348</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klingbeil</surname><given-names>AU</given-names></name><name><surname>John</surname><given-names>S</given-names></name><name><surname>Schneider</surname><given-names>MP</given-names></name><name><surname>Jacobi</surname><given-names>J</given-names></name><name><surname>Weidinger</surname><given-names>G</given-names></name><name><surname>Schmieder</surname><given-names>RE</given-names></name></person-group><article-title>AT1-receptor blockade improves augmentation index: a double-blind, randomized, controlled study</article-title><source>J Hypertens</source><year>2002</year><volume>20</volume><fpage>2423</fpage><lpage>2428</lpage><pub-id pub-id-type="pmid">12473867</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitsuhashi</surname><given-names>H</given-names></name><name><surname>Tamura</surname><given-names>K</given-names></name><name><surname>Yamauchi</surname><given-names>J</given-names></name><name><surname>Ozawa</surname><given-names>M</given-names></name><name><surname>Yanagi</surname><given-names>M</given-names></name><name><surname>Dejima</surname><given-names>T</given-names></name><name><surname>Wakui</surname><given-names>H</given-names></name><name><surname>Masuda</surname><given-names>S</given-names></name><name><surname>Azuma</surname><given-names>K</given-names></name><name><surname>Kanaoka</surname><given-names>T</given-names></name><name><surname>Ohsawa</surname><given-names>M</given-names></name><name><surname>Maeda</surname><given-names>A</given-names></name><name><surname>Tsurumi-Ikeya</surname><given-names>Y</given-names></name><name><surname>Okano</surname><given-names>Y</given-names></name><name><surname>Ishigami</surname><given-names>T</given-names></name><name><surname>Toya</surname><given-names>Y</given-names></name><name><surname>Tokita</surname><given-names>Y</given-names></name><name><surname>Ohnishi</surname><given-names>T</given-names></name><name><surname>Umemura</surname><given-names>S</given-names></name></person-group><article-title>Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis</article-title><source>Atherosclerosis</source><year>2009</year><volume>207</volume><fpage>186</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">19423110</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahonen</surname><given-names>M</given-names></name><name><surname>Ylitalo</surname><given-names>R</given-names></name><name><surname>Koobi</surname><given-names>T</given-names></name><name><surname>Turjanmaa</surname><given-names>V</given-names></name><name><surname>Ylitalo</surname><given-names>P</given-names></name></person-group><article-title>Influences of nonselective, beta(1)-selective and vasodilatory beta(1)-selective beta-blockers on arterial pulse wave velocity in normotensive subjects</article-title><source>Gen Pharmacol</source><year>2000</year><volume>35</volume><fpage>219</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">11827729</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ylitalo</surname><given-names>R</given-names></name><name><surname>Kahonen</surname><given-names>M</given-names></name><name><surname>Nieminen</surname><given-names>T</given-names></name><name><surname>Koobi</surname><given-names>T</given-names></name><name><surname>Ylitalo</surname><given-names>P</given-names></name><name><surname>Turjanmaa</surname><given-names>V</given-names></name></person-group><article-title>Effects of a mononitrate, a beta1-blocker and a dihydropyridine calcium channel blocker on cardiovascular responsiveness to passive orthostasis: a placebo-controlled double-blind study in normotensive volunteers</article-title><source>Arzneimittelforschung</source><year>2005</year><volume>55</volume><fpage>160</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">15819388</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>London</surname><given-names>GM</given-names></name><name><surname>Marchais</surname><given-names>SJ</given-names></name><name><surname>Guerin</surname><given-names>AP</given-names></name><name><surname>Metivier</surname><given-names>F</given-names></name><name><surname>Safar</surname><given-names>ME</given-names></name><name><surname>Fabiani</surname><given-names>F</given-names></name><name><surname>Froment</surname><given-names>L</given-names></name></person-group><article-title>Salt and water retention and calcium blockade in uremia</article-title><source>Circulation</source><year>1990</year><volume>82</volume><fpage>105</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">2364508</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asmar</surname><given-names>R</given-names></name><name><surname>Benetos</surname><given-names>A</given-names></name><name><surname>Brahimi</surname><given-names>M</given-names></name><name><surname>Chaouche</surname><given-names>K</given-names></name><name><surname>Safar</surname><given-names>M</given-names></name></person-group><article-title>Arterial and antihypertensive effects of nitrendipine: a double-blind comparison versus placebo</article-title><source>J Cardiovasc Pharmacol</source><year>1992</year><volume>20</volume><fpage>858</fpage><lpage>863</lpage><pub-id pub-id-type="pmid">1282585</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>NC</given-names></name><name><surname>Steeds</surname><given-names>RP</given-names></name><name><surname>Stewart</surname><given-names>PM</given-names></name><name><surname>Ferro</surname><given-names>CJ</given-names></name><name><surname>Townend</surname><given-names>JN</given-names></name></person-group><article-title>Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial</article-title><source>J Am Coll Cardiol</source><year>2009</year><volume>54</volume><fpage>505</fpage><lpage>512</lpage><pub-id pub-id-type="pmid">19643310</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahmud</surname><given-names>A</given-names></name><name><surname>Feely</surname><given-names>J</given-names></name></person-group><article-title>Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition</article-title><source>Am J Hypertens</source><year>2002</year><volume>15</volume><fpage>321</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">11991217</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>K</given-names></name><name><surname>Rajkumar</surname><given-names>C</given-names></name><name><surname>Fantin</surname><given-names>F</given-names></name><name><surname>Schiff</surname><given-names>R</given-names></name><name><surname>Bulpitt</surname><given-names>CJ</given-names></name></person-group><article-title>Irbesartan improves arterial compliance more than lisinopril</article-title><source>Vasc Health Risk Manag</source><year>2009</year><volume>5</volume><fpage>587</fpage><lpage>592</lpage><pub-id pub-id-type="pmid">19649309</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CH</given-names></name><name><surname>Ting</surname><given-names>CT</given-names></name><name><surname>Lin</surname><given-names>SJ</given-names></name><name><surname>Hsu</surname><given-names>TL</given-names></name><name><surname>Yin</surname><given-names>FC</given-names></name><name><surname>Siu</surname><given-names>CO</given-names></name><name><surname>Chou</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>SP</given-names></name><name><surname>Chang</surname><given-names>MS</given-names></name></person-group><article-title>Different effects of fosinopril and atenolol on wave reflections in hypertensive patients</article-title><source>Hypertension</source><year>1995</year><volume>25</volume><fpage>1034</fpage><lpage>1041</lpage><pub-id pub-id-type="pmid">7737712</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neal</surname><given-names>DA</given-names></name><name><surname>Brown</surname><given-names>MJ</given-names></name><name><surname>Wilkinson</surname><given-names>IB</given-names></name><name><surname>Byrne</surname><given-names>CD</given-names></name><name><surname>Alexander</surname><given-names>GJ</given-names></name></person-group><article-title>Hemodynamic effects of amlodipine, bisoprolol, and lisinopril in hypertensive patients after liver transplantation</article-title><source>Transplantation</source><year>2004</year><volume>77</volume><fpage>748</fpage><lpage>750</lpage><pub-id pub-id-type="pmid">15021839</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaiser</surname><given-names>T</given-names></name><name><surname>Heise</surname><given-names>T</given-names></name><name><surname>Nosek</surname><given-names>L</given-names></name><name><surname>Eckers</surname><given-names>U</given-names></name><name><surname>Sawicki</surname><given-names>PT</given-names></name></person-group><article-title>Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients</article-title><source>J Hypertens</source><year>2006</year><volume>24</volume><fpage>1397</fpage><lpage>1403</lpage><pub-id pub-id-type="pmid">16794490</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhakam</surname><given-names>Z</given-names></name><name><surname>McEniery</surname><given-names>CM</given-names></name><name><surname>Yasmin, Cockcroft</surname><given-names>JR</given-names></name><name><surname>Brown</surname><given-names>MJ</given-names></name><name><surname>Wilkinson</surname><given-names>IB</given-names></name></person-group><article-title>IB: Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity</article-title><source>Am J Hypertens</source><year>2006</year><volume>19</volume><fpage>214</fpage><lpage>219</lpage><pub-id pub-id-type="pmid">16448896</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Izzo</surname><given-names>JJ</given-names></name><name><surname>Rajpal</surname><given-names>M</given-names></name><name><surname>Karan</surname><given-names>S</given-names></name><name><surname>Srikakarlapudi</surname><given-names>S</given-names></name><name><surname>Osmond</surname><given-names>PJ</given-names></name></person-group><article-title>Hemodynamic and central blood pressure differences between carvedilol and valsartan added to lisinopril at rest and during exercise stress</article-title><source>J Am Soc Hypertens</source><year>2012</year><volume>6</volume><fpage>117</fpage><lpage>123</lpage><pub-id pub-id-type="pmid">22264722</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asmar</surname><given-names>RG</given-names></name><name><surname>Benetos</surname><given-names>A</given-names></name><name><surname>Chaouche-Teyara</surname><given-names>K</given-names></name><name><surname>Raveau-Landon</surname><given-names>CM</given-names></name><name><surname>Safar</surname><given-names>ME</given-names></name></person-group><article-title>Comparison of effects of felodipine versus hydrochlorothiazide on arterial diameter and pulse-wave velocity in essential hypertension</article-title><source>Am J Cardiol</source><year>1993</year><volume>72</volume><fpage>794</fpage><lpage>798</lpage><pub-id pub-id-type="pmid">8213511</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferguson</surname><given-names>JM</given-names></name><name><surname>Minas</surname><given-names>J</given-names></name><name><surname>Siapantas</surname><given-names>S</given-names></name><name><surname>Komesaroff</surname><given-names>PA</given-names></name><name><surname>Sudhir</surname><given-names>K</given-names></name></person-group><article-title>Effects of a fixed-dose ACE inhibitor-diuretic combination on ambulatory blood pressure and arterial properties in isolated systolic hypertension</article-title><source>J Cardiovasc Pharmacol</source><year>2008</year><volume>51</volume><fpage>590</fpage><lpage>595</lpage><pub-id pub-id-type="pmid">18520951</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajzer</surname><given-names>M</given-names></name><name><surname>Klocek</surname><given-names>M</given-names></name><name><surname>Kawecka-Jaszcz</surname><given-names>K</given-names></name></person-group><article-title>Effect of amlodipine, quinapril, and losartan on pulse wave velocity and plasma collagen markers in patients with mild-to-moderate arterial hypertension</article-title><source>Am J Hypertens</source><year>2003</year><volume>16</volume><fpage>439</fpage><lpage>444</lpage><pub-id pub-id-type="pmid">12799091</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takami</surname><given-names>T</given-names></name><name><surname>Shigemasa</surname><given-names>M</given-names></name></person-group><article-title>Efficacy of various antihypertensive agents as evaluated by indices of vascular stiffness in elderly hypertensive patients</article-title><source>Hypertens Res</source><year>2003</year><volume>26</volume><fpage>609</fpage><lpage>614</lpage><pub-id pub-id-type="pmid">14567499</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anan</surname><given-names>F</given-names></name><name><surname>Takahashi</surname><given-names>N</given-names></name><name><surname>Ooie</surname><given-names>T</given-names></name><name><surname>Yufu</surname><given-names>K</given-names></name><name><surname>Hara</surname><given-names>M</given-names></name><name><surname>Nakagawa</surname><given-names>M</given-names></name><name><surname>Yonemochi</surname><given-names>H</given-names></name><name><surname>Saikawa</surname><given-names>T</given-names></name><name><surname>Yoshimatsu</surname><given-names>H</given-names></name></person-group><article-title>Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension</article-title><source>Eur J Clin Pharmacol</source><year>2005</year><volume>61</volume><fpage>353</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">15918057</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rehman</surname><given-names>A</given-names></name><name><surname>Ismail</surname><given-names>SB</given-names></name><name><surname>Naing</surname><given-names>L</given-names></name><name><surname>Roshan</surname><given-names>TM</given-names></name><name><surname>Rahman</surname><given-names>AR</given-names></name></person-group><article-title>Reduction in arterial stiffness with angiotensin II antagonism and converting enzyme inhibition</article-title><source>A comparative study among Malay hypertensive subjects with a known genetic profile. Am J Hypertens</source><year>2007</year><volume>20</volume><fpage>184</fpage><lpage>189</lpage></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>SM</given-names></name><name><surname>Du</surname><given-names>M</given-names></name><name><surname>Chu</surname><given-names>WW</given-names></name><name><surname>Cheng</surname><given-names>XM</given-names></name></person-group><article-title>Perindopril, amlodipine and telmisartan improve arterial stiffness in patients with hypertension (in Chinese)</article-title><source>Zhonghua Xin Xue Guan Bing Za Zhi</source><year>2009</year><volume>37</volume><fpage>908</fpage><lpage>912</lpage><pub-id pub-id-type="pmid">20137542</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackenzie</surname><given-names>IS</given-names></name><name><surname>McEniery</surname><given-names>CM</given-names></name><name><surname>Dhakam</surname><given-names>Z</given-names></name><name><surname>Brown</surname><given-names>MJ</given-names></name><name><surname>Cockcroft</surname><given-names>JR</given-names></name><name><surname>Wilkinson</surname><given-names>IB</given-names></name></person-group><article-title>Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension</article-title><source>Hypertension</source><year>2009</year><volume>54</volume><fpage>409</fpage><lpage>413</lpage><pub-id pub-id-type="pmid">19487582</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>London</surname><given-names>GM</given-names></name><name><surname>Pannier</surname><given-names>B</given-names></name><name><surname>Guerin</surname><given-names>AP</given-names></name><name><surname>Marchais</surname><given-names>SJ</given-names></name><name><surname>Safar</surname><given-names>ME</given-names></name><name><surname>Cuche</surname><given-names>JL</given-names></name></person-group><article-title>Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease</article-title><source>Comparative effects of ACE inhibition and calcium channel blockade. Circulation</source><year>1994</year><volume>90</volume><fpage>2786</fpage><lpage>2796</lpage></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morimoto</surname><given-names>S</given-names></name><name><surname>Maki</surname><given-names>K</given-names></name><name><surname>Aota</surname><given-names>Y</given-names></name><name><surname>Sakuma</surname><given-names>T</given-names></name><name><surname>Iwasaka</surname><given-names>T</given-names></name></person-group><article-title>Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function</article-title><source>Hypertens Res</source><year>2008</year><volume>31</volume><fpage>1603</fpage><lpage>1610</lpage><pub-id pub-id-type="pmid">18971536</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breithaupt-Grogler</surname><given-names>K</given-names></name><name><surname>Leschinger</surname><given-names>M</given-names></name><name><surname>Belz</surname><given-names>GG</given-names></name><name><surname>Butzer</surname><given-names>R</given-names></name><name><surname>Erb</surname><given-names>K</given-names></name><name><surname>de May</surname><given-names>C</given-names></name><name><surname>Sinn</surname><given-names>W</given-names></name></person-group><article-title>Influence of antihypertensive therapy with cilazapril and hydrochlorothiazide on the stiffness of the aorta</article-title><source>Cardiovasc Drugs Ther</source><year>1996</year><volume>10</volume><fpage>49</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">8723170</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>XJ</given-names></name><name><surname>Li</surname><given-names>QY</given-names></name><name><surname>Zhang</surname><given-names>YQ</given-names></name><name><surname>Liu</surname><given-names>GZ</given-names></name><name><surname>Liu</surname><given-names>LS</given-names></name></person-group><article-title>The comparison of the effect of enalapril and indapamide on the peripheral blood pressure and central blood pressure through pulse wave analysis (in Chinese)</article-title><source>Zhonghua Xin Xue Guan Bing Za Zhi</source><year>2005</year><volume>33</volume><fpage>885</fpage><lpage>888</lpage><pub-id pub-id-type="pmid">16266472</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kostka-Jeziorny</surname><given-names>K</given-names></name><name><surname>Uruski</surname><given-names>P</given-names></name><name><surname>Tykarski</surname><given-names>A</given-names></name></person-group><article-title>Effect of allopurinol on blood pressure and aortic compliance in hypertensive patients</article-title><source>Blood Press</source><year>2011</year><volume>20</volume><fpage>104</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">21405957</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boutouyrie</surname><given-names>P</given-names></name><name><surname>Achouba</surname><given-names>A</given-names></name><name><surname>Trunet</surname><given-names>P</given-names></name><name><surname>Laurent</surname><given-names>S</given-names></name></person-group><article-title>Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study</article-title><source>Hypertension</source><year>2010</year><volume>55</volume><fpage>1314</fpage><lpage>1322</lpage><pub-id pub-id-type="pmid">20404219</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vitale</surname><given-names>C</given-names></name><name><surname>Marazzi</surname><given-names>G</given-names></name><name><surname>Iellamo</surname><given-names>F</given-names></name><name><surname>Spoletini</surname><given-names>I</given-names></name><name><surname>Dall'Armi</surname><given-names>V</given-names></name><name><surname>Fini</surname><given-names>M</given-names></name><name><surname>Volterrani</surname><given-names>M</given-names></name></person-group><article-title>Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: the NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study</article-title><source>Int J Cardiol</source><year>2012</year><volume>155</volume><fpage>279</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">22078979</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munakata</surname><given-names>M</given-names></name><name><surname>Nagasaki</surname><given-names>A</given-names></name><name><surname>Nunokawa</surname><given-names>T</given-names></name><name><surname>Sakuma</surname><given-names>T</given-names></name><name><surname>Kato</surname><given-names>H</given-names></name><name><surname>Yoshinaga</surname><given-names>K</given-names></name><name><surname>Toyota</surname><given-names>T</given-names></name></person-group><article-title>Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients</article-title><source>Am J Hypertens</source><year>2004</year><volume>17</volume><fpage>1050</fpage><lpage>1055</lpage><pub-id pub-id-type="pmid">15533733</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ichihara</surname><given-names>A</given-names></name><name><surname>Kaneshiro</surname><given-names>Y</given-names></name><name><surname>Takemitsu</surname><given-names>T</given-names></name><name><surname>Sakoda</surname><given-names>M</given-names></name></person-group><article-title>Effects of amlodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients</article-title><source>J Hum Hypertens</source><year>2006</year><volume>20</volume><fpage>787</fpage><lpage>794</lpage><pub-id pub-id-type="pmid">16810279</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morimoto</surname><given-names>S</given-names></name><name><surname>Yano</surname><given-names>Y</given-names></name><name><surname>Maki</surname><given-names>K</given-names></name><name><surname>Sawada</surname><given-names>K</given-names></name></person-group><article-title>Renal and vascular protective effects of telmisartan in patients with essential hypertension</article-title><source>Hypertens Res</source><year>2006</year><volume>29</volume><fpage>567</fpage><lpage>572</lpage><pub-id pub-id-type="pmid">17137211</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosch</surname><given-names>M</given-names></name><name><surname>Levers</surname><given-names>A</given-names></name><name><surname>Lang</surname><given-names>D</given-names></name><name><surname>Bartels</surname><given-names>V</given-names></name><name><surname>Rahn</surname><given-names>KH</given-names></name><name><surname>Pavenstadt</surname><given-names>H</given-names></name><name><surname>Hausberg</surname><given-names>M</given-names></name></person-group><article-title>A randomized, double-blind study of valsartan versus metoprolol on arterial distensibility and endothelial function in essential hypertension</article-title><source>Nephrol Dial Transplant</source><year>2008</year><volume>23</volume><fpage>2280</fpage><lpage>2285</lpage><pub-id pub-id-type="pmid">18194979</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishii</surname><given-names>H</given-names></name><name><surname>Tsukada</surname><given-names>T</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name></person-group><article-title>Angiotensin II type-I receptor blocker, candesartan, improves brachial-ankle pulse wave velocity independent of its blood pressure lowering effects in type 2 diabetes patients</article-title><source>Intern Med</source><year>2008</year><volume>47</volume><fpage>2013</fpage><lpage>2018</lpage><pub-id pub-id-type="pmid">19043252</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>MP</given-names></name><name><surname>Delles</surname><given-names>C</given-names></name><name><surname>Klingbeil</surname><given-names>AU</given-names></name><name><surname>Ludwig</surname><given-names>M</given-names></name><name><surname>Kolloch</surname><given-names>RE</given-names></name><name><surname>Krekler</surname><given-names>M</given-names></name><name><surname>Stumpe</surname><given-names>KO</given-names></name><name><surname>Schmieder</surname><given-names>RE</given-names></name></person-group><article-title>Effect of angiotensin receptor blockade on central haemodynamics in essential hypertension: results of a randomised trial</article-title><source>J Renin Angiotensin Aldosterone Syst</source><year>2008</year><volume>9</volume><fpage>49</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">18404609</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomiyama</surname><given-names>H</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Yamada</surname><given-names>J</given-names></name><name><surname>Matsumoto</surname><given-names>C</given-names></name><name><surname>Odaira</surname><given-names>M</given-names></name><name><surname>Shiina</surname><given-names>K</given-names></name><name><surname>Yamashina</surname><given-names>A</given-names></name></person-group><article-title>Arterial-cardiac destiffening following long-term antihypertensive treatment</article-title><source>Am J Hypertens</source><year>2011</year><volume>24</volume><fpage>1080</fpage><lpage>1086</lpage><pub-id pub-id-type="pmid">21677695</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merli</surname><given-names>I</given-names></name><name><surname>Simon</surname><given-names>A</given-names></name><name><surname>Del</surname><given-names>PM</given-names></name><name><surname>Brautigam</surname><given-names>M</given-names></name><name><surname>Welzel</surname><given-names>D</given-names></name><name><surname>Levenson</surname><given-names>J</given-names></name></person-group><article-title>Intrinsic effect of antihypertensive treatment with isradipine and metoprololon large artery geometric and elastic properties</article-title><source>Clin Pharmacol Ther</source><year>1993</year><volume>54</volume><fpage>76</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">8330468</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>WB</given-names></name><name><surname>Duprez</surname><given-names>D</given-names></name><name><surname>St Hillaire</surname><given-names>R</given-names></name><name><surname>Krause</surname><given-names>S</given-names></name><name><surname>Roniker</surname><given-names>B</given-names></name><name><surname>Kuse-Hamilton</surname><given-names>J</given-names></name><name><surname>Weber</surname><given-names>MA</given-names></name></person-group><article-title>Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension</article-title><source>Hypertension</source><year>2003</year><volume>41</volume><fpage>1021</fpage><lpage>1026</lpage><pub-id pub-id-type="pmid">12682082</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>B</given-names></name><name><surname>Lacy</surname><given-names>PS</given-names></name><name><surname>Thom</surname><given-names>SM</given-names></name><name><surname>Cruickshank</surname><given-names>K</given-names></name><name><surname>Stanton</surname><given-names>A</given-names></name><name><surname>Collier</surname><given-names>D</given-names></name><name><surname>Hughes</surname><given-names>AD</given-names></name><name><surname>Thurston</surname><given-names>H</given-names></name><name><surname>O'Rourke</surname><given-names>M</given-names></name></person-group><article-title>Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study</article-title><source>Circulation</source><year>2006</year><volume>113</volume><fpage>1213</fpage><lpage>1225</lpage><pub-id pub-id-type="pmid">16476843</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaneshiro</surname><given-names>Y</given-names></name><name><surname>Ichihara</surname><given-names>A</given-names></name><name><surname>Sakoda</surname><given-names>M</given-names></name><name><surname>Kurauchi-Mito</surname><given-names>A</given-names></name><name><surname>Kinouchi</surname><given-names>K</given-names></name><name><surname>Itoh</surname><given-names>H</given-names></name></person-group><article-title>Add-on benefits of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1/2 patients treated with valsartan</article-title><source>Kidney Blood Press Res</source><year>2009</year><volume>32</volume><fpage>51</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">19258723</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doi</surname><given-names>M</given-names></name><name><surname>Miyoshi</surname><given-names>T</given-names></name><name><surname>Hirohata</surname><given-names>S</given-names></name><name><surname>Kamikawa</surname><given-names>S</given-names></name><name><surname>Usui</surname><given-names>S</given-names></name><name><surname>Kaji</surname><given-names>Y</given-names></name><name><surname>Sakane</surname><given-names>K</given-names></name><name><surname>Ogawa</surname><given-names>H</given-names></name><name><surname>Ninomiya</surname><given-names>Y</given-names></name><name><surname>Kusachi</surname><given-names>S</given-names></name></person-group><article-title>Combination therapy of calcium channel blocker and angiotensin II receptor blocker reduces augmentation index in hypertensive patients</article-title><source>Am J Med Sci</source><year>2010</year><volume>339</volume><fpage>433</fpage><lpage>439</lpage><pub-id pub-id-type="pmid">20234301</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsui</surname><given-names>Y</given-names></name><name><surname>Eguchi</surname><given-names>K</given-names></name><name><surname>O'Rourke</surname><given-names>MF</given-names></name><name><surname>Ishikawa</surname><given-names>J</given-names></name><name><surname>Shimada</surname><given-names>K</given-names></name><name><surname>Kario</surname><given-names>K</given-names></name></person-group><article-title>Association between aldosterone induced by antihypertensive medication and arterial stiffness reduction: the J-CORE study</article-title><source>Atherosclerosis</source><year>2011</year><volume>215</volume><fpage>184</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">21241987</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asmar</surname><given-names>RG</given-names></name><name><surname>London</surname><given-names>GM</given-names></name><name><surname>O'Rourke</surname><given-names>ME</given-names></name><name><surname>Safar</surname><given-names>ME</given-names></name></person-group><article-title>Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol</article-title><source>Hypertension</source><year>2001</year><volume>38</volume><fpage>922</fpage><lpage>926</lpage><pub-id pub-id-type="pmid">11641310</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>FH</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>LH</given-names></name><name><surname>Wang</surname><given-names>JG</given-names></name></person-group><article-title>Impact of heart rate on central hemodynamics and stroke: a meta-analysis of &#x003b2;-blocker trials</article-title><source>Am J Hypertens</source><year>2013</year><volume>26</volume><fpage>118</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">23382335</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Randomized placebo-controlled double-blind cross-over studies</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th align="left" rowspan="1" colspan="1">First author [Ref.]</th><th align="left" rowspan="1" colspan="1">Year</th><th align="left" rowspan="1" colspan="1">Subjects</th><th align="left" rowspan="1" colspan="1">Patients, n</th><th align="left" rowspan="1" colspan="1">Antihypertensive treatment(s)</th><th colspan="2" align="left" rowspan="1">Results<hr/></th></tr><tr valign="top"><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">arterial stiffness</th><th align="left" rowspan="1" colspan="1">wave reflections</th></tr></thead><tbody><tr><td colspan="7" align="left" rowspan="1"><italic>ACEIs</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Pannier [<xref rid="B3" ref-type="bibr">3</xref>]</td><td align="left" rowspan="1" colspan="1">2001</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">perindopril</td><td align="left" rowspan="1" colspan="1">AUC cfPWV NS</td><td align="left" rowspan="1" colspan="1">AUC AIx perindopril better</td></tr><tr><td align="left" rowspan="1" colspan="1">Deary [<xref rid="B4" ref-type="bibr">4</xref>]</td><td align="left" rowspan="1" colspan="1">2002</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">lisinopril</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Morgan [<xref rid="B5" ref-type="bibr">5</xref>]</td><td align="left" rowspan="1" colspan="1">2004</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">ACEIs</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Hirata [<xref rid="B6" ref-type="bibr">6</xref>]</td><td align="left" rowspan="1" colspan="1">2005</td><td align="left" rowspan="1" colspan="1">CAD</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">ramipril</td><td align="left" rowspan="1" colspan="1">cfPWV ramipril better</td><td align="left" rowspan="1" colspan="1">AIx and AIx@HR75 ramipril better</td></tr><tr><td align="left" rowspan="1" colspan="1">Turner [<xref rid="B7" ref-type="bibr">7</xref>]</td><td align="left" rowspan="1" colspan="1">2006</td><td align="left" rowspan="1" colspan="1">intracranial aneurysms</td><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">perindopril</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" colspan="7" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>ARBs</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Asmar [<xref rid="B8" ref-type="bibr">8</xref>]</td><td align="left" rowspan="1" colspan="1">2002</td><td align="left" rowspan="1" colspan="1">EH/DM</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">telmisartan</td><td align="left" rowspan="1" colspan="1">cfPWV telmisartan better</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Rajagopalan [<xref rid="B9" ref-type="bibr">9</xref>]</td><td align="left" rowspan="1" colspan="1">2006</td><td align="left" rowspan="1" colspan="1">healthy volunteers</td><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1">valsartan</td><td align="left" rowspan="1" colspan="1">cfPWV NS</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Turner [<xref rid="B7" ref-type="bibr">7</xref>]</td><td align="left" rowspan="1" colspan="1">2006</td><td align="left" rowspan="1" colspan="1">intracranial aneurysms</td><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">irbesartan</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Kaufman [<xref rid="B10" ref-type="bibr">10</xref>]</td><td align="left" rowspan="1" colspan="1">2010</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">losartan</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" colspan="7" rowspan="1"><hr/></td></tr><tr><td colspan="7" align="left" rowspan="1"><italic>&#x003b2;-Blockers</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Asmar [<xref rid="B11" ref-type="bibr">11</xref>]</td><td align="left" rowspan="1" colspan="1">1991</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">bisoprolol</td><td align="left" rowspan="1" colspan="1">cfPWV bisoprolol better</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Pannier [<xref rid="B3" ref-type="bibr">3</xref>]</td><td align="left" rowspan="1" colspan="1">2001</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">atenolol</td><td align="left" rowspan="1" colspan="1">AUC cfPWV atenolol better</td><td align="left" rowspan="1" colspan="1">AUC AIx NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Deary [<xref rid="B4" ref-type="bibr">4</xref>]</td><td align="left" rowspan="1" colspan="1">2002</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">bisoprolol</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx bisoprolol better</td></tr><tr><td align="left" rowspan="1" colspan="1">Morgan [<xref rid="B5" ref-type="bibr">5</xref>]</td><td align="left" rowspan="1" colspan="1">2004</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">&#x003b2;-blockers</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Hirata [<xref rid="B6" ref-type="bibr">6</xref>]</td><td align="left" rowspan="1" colspan="1">2005</td><td align="left" rowspan="1" colspan="1">CAD</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">atenolol</td><td align="left" rowspan="1" colspan="1">cfPWV atenolol better</td><td align="left" rowspan="1" colspan="1">AIx atenolol worse; AIx@HR75 NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Dhakam [<xref rid="B12" ref-type="bibr">12</xref>]</td><td align="left" rowspan="1" colspan="1">2008</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">nebivolol atenolol</td><td align="left" rowspan="1" colspan="1">aPWV nebivolol better aPWV atenolol better</td><td align="left" rowspan="1" colspan="1">AIx nebivolol worse AIx atenolol worse</td></tr><tr><td align="left" colspan="7" rowspan="1"><hr/></td></tr><tr><td colspan="7" align="left" rowspan="1"><italic>CCBs</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Deary [<xref rid="B4" ref-type="bibr">4</xref>]</td><td align="left" rowspan="1" colspan="1">2002</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">amlodipine</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Morgan [<xref rid="B5" ref-type="bibr">5</xref>]</td><td align="left" rowspan="1" colspan="1">2004</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">CCBs</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" colspan="7" rowspan="1"><hr/></td></tr><tr><td colspan="7" align="left" rowspan="1"><italic>Diuretics</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Deary [<xref rid="B4" ref-type="bibr">4</xref>]</td><td align="left" rowspan="1" colspan="1">2002</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">bendrofluazide</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Morgan [<xref rid="B5" ref-type="bibr">5</xref>]</td><td align="left" rowspan="1" colspan="1">2004</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">diuretics</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Davies [<xref rid="B13" ref-type="bibr">13</xref>]</td><td align="left" rowspan="1" colspan="1">2005</td><td align="left" rowspan="1" colspan="1">EH/DM</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">spironolactone</td><td align="left" rowspan="1" colspan="1">crPWV spironolactone better</td><td align="left" rowspan="1" colspan="1">not measured</td></tr></tbody></table><table-wrap-foot><fn><p>ACEIs = ACE inhibitors; AIx = augmentation index; AIx@HR75 = AIx corrected for heart rate of 75 beats/min; aPWV = aortic pulse wave velocity; AUC = area under the curve; CAD = coronary artery disease; cfPWV = carotid-femoral pulse wave velocity; crPWV = carotid-radial pulse wave velocity; DM = diabetes mellitus; EH = essential hypertension; NS = not significantly different.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Randomized placebo-controlled parallel-group comparison studies</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th align="left" rowspan="1" colspan="1">First author [Ref.]</th><th align="left" rowspan="1" colspan="1">Year</th><th align="left" rowspan="1" colspan="1">Design</th><th align="left" rowspan="1" colspan="1">Subjects</th><th align="left" rowspan="1" colspan="1">Patients, n</th><th align="left" rowspan="1" colspan="1">Antihypertensive treatment(s)</th><th colspan="2" align="left" rowspan="1">Results<hr/></th></tr><tr valign="top"><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">arterial stiffness</th><th align="left" rowspan="1" colspan="1">wave reflections</th></tr></thead><tbody><tr><td colspan="8" align="left" rowspan="1"><italic>ACEIs</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Kahonen [<xref rid="B14" ref-type="bibr">14</xref>]</td><td align="left" rowspan="1" colspan="1">1998</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">healthy volunteers</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">captopril</td><td align="left" rowspan="1" colspan="1">cfPWV captopril better</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Dart [<xref rid="B15" ref-type="bibr">15</xref>]</td><td align="left" rowspan="1" colspan="1">2001</td><td align="left" rowspan="1" colspan="1">open</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">111</td><td align="left" rowspan="1" colspan="1">perindopril</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Ichihara [<xref rid="B16" ref-type="bibr">16</xref>]</td><td align="left" rowspan="1" colspan="1">2005</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">hemodialysis patients</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">trandolapril</td><td align="left" rowspan="1" colspan="1">baPWV trandolapril better</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Yu [<xref rid="B17" ref-type="bibr">17</xref>]</td><td align="left" rowspan="1" colspan="1">2006</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">hemodialysis patients</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">ramipril</td><td align="left" rowspan="1" colspan="1">cfPWV NS</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Tsang [<xref rid="B18" ref-type="bibr">18</xref>]</td><td align="left" rowspan="1" colspan="1">2006</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">IDD</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">quinapril</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Ahimastos [<xref rid="B19" ref-type="bibr">19</xref>]</td><td align="left" rowspan="1" colspan="1">2007</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">Marfan syndrome</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">perindopril</td><td align="left" rowspan="1" colspan="1">cfPWV and faPWV perindopril better</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Rahman [<xref rid="B20" ref-type="bibr">20</xref>]</td><td align="left" rowspan="1" colspan="1">2007</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">DM</td><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">ramipril</td><td align="left" rowspan="1" colspan="1">cfPWV NS</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IGT</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">ramipril</td><td align="left" rowspan="1" colspan="1">cfPWV NS</td><td align="left" rowspan="1" colspan="1">AIx ramipril better</td></tr><tr><td align="left" rowspan="1" colspan="1">Mitchell [<xref rid="B21" ref-type="bibr">21</xref>]</td><td align="left" rowspan="1" colspan="1">2007</td><td align="left" rowspan="1" colspan="1">open</td><td align="left" rowspan="1" colspan="1">CAD</td><td align="left" rowspan="1" colspan="1">300</td><td align="left" rowspan="1" colspan="1">trandolapril</td><td align="left" rowspan="1" colspan="1">cfPWV trandolapril better</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Ahimastos [<xref rid="B22" ref-type="bibr">22</xref>]</td><td align="left" rowspan="1" colspan="1">2008</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">PAD</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">ramipril</td><td align="left" rowspan="1" colspan="1">cfPWV ramipril better</td><td align="left" rowspan="1" colspan="1">AIx ramipril better</td></tr><tr><td align="left" colspan="8" rowspan="1"><hr/></td></tr><tr><td colspan="8" align="left" rowspan="1"><italic>ARBs</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Klingbeil [<xref rid="B23" ref-type="bibr">23</xref>]</td><td align="left" rowspan="1" colspan="1">2002</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">valsartan</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx valsartan better</td></tr><tr><td align="left" rowspan="1" colspan="1">Ichihara [<xref rid="B16" ref-type="bibr">16</xref>]</td><td align="left" rowspan="1" colspan="1">2005</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">hemodialysis patients</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">losartan</td><td align="left" rowspan="1" colspan="1">baPWV NS</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Mitsuhashi [<xref rid="B24" ref-type="bibr">24</xref>]</td><td align="left" rowspan="1" colspan="1">2009</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">EH/hemodialysis patients</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">losartan</td><td align="left" rowspan="1" colspan="1">baPWV NS</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" colspan="8" rowspan="1"><hr/></td></tr><tr><td colspan="8" align="left" rowspan="1"><italic>&#x000df;-Blockers</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Kahonen [<xref rid="B14" ref-type="bibr">14</xref>]</td><td align="left" rowspan="1" colspan="1">1998</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">healthy volunteers</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">propranolol</td><td align="left" rowspan="1" colspan="1">cfPWV propranolol better</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Kahonen [<xref rid="B25" ref-type="bibr">25</xref>]</td><td align="left" rowspan="1" colspan="1">2000</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">healthy volunteers</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">bisoprolol, celiprolol, and propranolol</td><td align="left" rowspan="1" colspan="1">cfPWV bisoprolol and propranolol better; celiprolol worse</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Ylitalo [<xref rid="B26" ref-type="bibr">26</xref>]</td><td align="left" rowspan="1" colspan="1">2005</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">healthy volunteers</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">bisoprolol</td><td align="left" rowspan="1" colspan="1">cfPWV NS</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" colspan="8" rowspan="1"><hr/></td></tr><tr><td colspan="8" align="left" rowspan="1"><italic>CCBs</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">London [<xref rid="B27" ref-type="bibr">27</xref>]</td><td align="left" rowspan="1" colspan="1">1990</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">ESRD</td><td align="left" rowspan="1" colspan="1">37</td><td align="left" rowspan="1" colspan="1">nitrendipine</td><td align="left" rowspan="1" colspan="1">cfPWV nitrendipine better</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Asmar [<xref rid="B28" ref-type="bibr">28</xref>]</td><td align="left" rowspan="1" colspan="1">1992</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">nitrendipine</td><td align="left" rowspan="1" colspan="1">cfPWV nitrendipine better</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Kahonen [<xref rid="B14" ref-type="bibr">14</xref>]</td><td align="left" rowspan="1" colspan="1">1998</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">healthy volunteers</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">verapamil</td><td align="left" rowspan="1" colspan="1">cfPWV NS</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Ylitalo [<xref rid="B26" ref-type="bibr">26</xref>]</td><td align="left" rowspan="1" colspan="1">2005</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">healthy volunteers</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">nisoldipine</td><td align="left" rowspan="1" colspan="1">cfPWV NS</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" colspan="8" rowspan="1"><hr/></td></tr><tr><td colspan="8" align="left" rowspan="1"><italic>Diuretics</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Klingbeil [<xref rid="B23" ref-type="bibr">23</xref>]</td><td align="left" rowspan="1" colspan="1">2002</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">hydrochlorothiazide</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Edwards [<xref rid="B29" ref-type="bibr">29</xref>]</td><td align="left" rowspan="1" colspan="1">2009</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">CKD</td><td align="left" rowspan="1" colspan="1">112</td><td align="left" rowspan="1" colspan="1">spironolactone</td><td align="left" rowspan="1" colspan="1">cfPWV spironolactone better</td><td align="left" rowspan="1" colspan="1">AIx spironolactone better</td></tr></tbody></table><table-wrap-foot><fn><p>ACEIs = ACE inhibitors; AIx = augmentation index; baPWV = brachial-ankle pulse wave velocity; CAD = coronary artery disease; cfPWV = carotid-femoral pulse wave velocity; CKD = chronic kidney disease; DB = double-blinded; DM = diabetes mellitus; EH = essential hypertension; ESRD = end-stage renal dysfunction; faPWV = femoral-dorsalis pedis pulse wave velocity; IDD = isolated diastolic dysfunction; IGT = impaired glucose tolerance; NS = not significantly different; PAD = peripheral artery disease.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Randomized actively-controlled cross-over studies</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th align="left" rowspan="1" colspan="1">First author [Ref.]</th><th align="left" rowspan="1" colspan="1">Year</th><th align="left" rowspan="1" colspan="1">Design</th><th align="left" rowspan="1" colspan="1">Subjects</th><th align="left" rowspan="1" colspan="1">Patients, n</th><th align="left" rowspan="1" colspan="1">Comparison(s)</th><th colspan="2" align="left" rowspan="1">Results<hr/></th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">arterial stiffness</th><th align="left" rowspan="1" colspan="1">wave reflections</th></tr></thead><tbody><tr><td colspan="8" align="left" rowspan="1">ACEIs</td></tr><tr><td colspan="8" align="left" rowspan="1"><italic>vs. ARBs</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Mahmud [<xref rid="B30" ref-type="bibr">30</xref>]</td><td align="left" rowspan="1" colspan="1">2002</td><td align="left" rowspan="1" colspan="1">SB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">captopril vs. valsartan</td><td align="left" rowspan="1" colspan="1">cfPWV NS</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Turner [<xref rid="B7" ref-type="bibr">7</xref>]</td><td align="left" rowspan="1" colspan="1">2006</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">intracranial aneurysms</td><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">perindopril vs. irbesartan</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Ali [<xref rid="B31" ref-type="bibr">31</xref>]</td><td align="left" rowspan="1" colspan="1">2009</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">lisinopril vs. irbesartan</td><td align="left" rowspan="1" colspan="1">cfPWV NS</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" colspan="8" rowspan="1"><hr/></td></tr><tr><td colspan="8" align="left" rowspan="1"><italic>vs. &#x000df;-blockers</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Chen [<xref rid="B32" ref-type="bibr">32</xref>]</td><td align="left" rowspan="1" colspan="1">1995</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">79</td><td align="left" rowspan="1" colspan="1">fosinopril vs. atenolol</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx fosinopril better</td></tr><tr><td align="left" rowspan="1" colspan="1">Pannier [<xref rid="B3" ref-type="bibr">3</xref>]</td><td align="left" rowspan="1" colspan="1">2001</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">perindopril vs. atenolol</td><td align="left" rowspan="1" colspan="1">cfPWV atenolol</td><td align="left" rowspan="1" colspan="1">AUC AIx per-idopril</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">better</td><td align="left" rowspan="1" colspan="1">better</td></tr><tr><td align="left" rowspan="1" colspan="1">Deary [<xref rid="B4" ref-type="bibr">4</xref>]</td><td align="left" rowspan="1" colspan="1">2002</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">lisinopril vs. bisoprolol</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx lisinopril better</td></tr><tr><td align="left" rowspan="1" colspan="1">Morgan [<xref rid="B5" ref-type="bibr">5</xref>]</td><td align="left" rowspan="1" colspan="1">2004</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">ACEIs vs. &#x003b2;-blockers</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx ACEIs better</td></tr><tr><td align="left" rowspan="1" colspan="1">Neal [<xref rid="B33" ref-type="bibr">33</xref>]</td><td align="left" rowspan="1" colspan="1">2004</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH/liver transplantation</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">lisinopril vs. bisoprolol</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx lisinopril better</td></tr><tr><td align="left" rowspan="1" colspan="1">Hirata [<xref rid="B6" ref-type="bibr">6</xref>]</td><td align="left" rowspan="1" colspan="1">2005</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">CAD</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">ramipril vs. atenolol</td><td align="left" rowspan="1" colspan="1">cfPWV NS</td><td align="left" rowspan="1" colspan="1">AIx and AIx@HR75 ramipril better</td></tr><tr><td align="left" rowspan="1" colspan="1">Kaiser [<xref rid="B34" ref-type="bibr">34</xref>]</td><td align="left" rowspan="1" colspan="1">2006</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH/DM</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">enalapril vs. nebivolol</td><td align="left" rowspan="1" colspan="1">cfPWV NS</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" colspan="8" rowspan="1"><hr/></td></tr><tr><td colspan="8" align="left" rowspan="1"><italic>vs. CCBs</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Deary [<xref rid="B4" ref-type="bibr">4</xref>]</td><td align="left" rowspan="1" colspan="1">2002</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">lisinopril vs. amlodipine</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Morgan [<xref rid="B5" ref-type="bibr">5</xref>]</td><td align="left" rowspan="1" colspan="1">2004</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">ACEIs vs. CCBs</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Neal [<xref rid="B33" ref-type="bibr">33</xref>]</td><td align="left" rowspan="1" colspan="1">2004</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH/liver transplantation</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">lisinopril vs. amlodipine</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" colspan="8" rowspan="1"><hr/></td></tr><tr><td colspan="8" align="left" rowspan="1"><italic>vs. diuretics</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Deary [<xref rid="B4" ref-type="bibr">4</xref>]</td><td align="left" rowspan="1" colspan="1">2002</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">lisinopril vs. bendrofluazide</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Morgan [<xref rid="B5" ref-type="bibr">5</xref>]</td><td align="left" rowspan="1" colspan="1">2004</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">ACEIs vs. diuretics</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" colspan="8" rowspan="1"><hr/></td></tr><tr><td colspan="8" align="left" rowspan="1"><bold>ARBs</bold></td></tr><tr><td colspan="8" align="left" rowspan="1"><italic>vs. &#x000df;-blockers</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Dhakam [<xref rid="B35" ref-type="bibr">35</xref>]</td><td align="left" rowspan="1" colspan="1">2006</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">eprosartan vs. atenolol</td><td align="left" rowspan="1" colspan="1">cfPWV atenolol better</td><td align="left" rowspan="1" colspan="1">AIx eprosartan better</td></tr><tr><td align="left" rowspan="1" colspan="1">Izzo [<xref rid="B36" ref-type="bibr">36</xref>]</td><td align="left" rowspan="1" colspan="1">2012</td><td align="left" rowspan="1" colspan="1">SB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">lisinopril + valsartan vs. lisinopril + carvedilol</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" colspan="8" rowspan="1"><hr/></td></tr><tr><td colspan="8" align="left" rowspan="1"><bold>&#x003b2;-Blockers</bold></td></tr><tr><td colspan="8" align="left" rowspan="1"><italic>vs. &#x000df;-blockers</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Dhakam [<xref rid="B12" ref-type="bibr">12</xref>]</td><td align="left" rowspan="1" colspan="1">2008</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">atenolol vs. nebivolol</td><td align="left" rowspan="1" colspan="1">aPWV NS</td><td align="left" rowspan="1" colspan="1">AIx nebivolol better</td></tr><tr><td align="left" colspan="8" rowspan="1"><hr/></td></tr><tr><td colspan="8" align="left" rowspan="1"><italic>vs. CCBs</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Deary [<xref rid="B4" ref-type="bibr">4</xref>]</td><td align="left" rowspan="1" colspan="1">2002</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">bisoprolol vs. amlodipine</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx amlodipine better</td></tr><tr><td align="left" rowspan="1" colspan="1">Morgan [<xref rid="B5" ref-type="bibr">5</xref>]</td><td align="left" rowspan="1" colspan="1">2004</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">&#x000df;-blockers vs. CCBs</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx CCBs better</td></tr><tr><td align="left" rowspan="1" colspan="1">Neal [<xref rid="B33" ref-type="bibr">33</xref>]</td><td align="left" rowspan="1" colspan="1">2004</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH/liver transplantation</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">bisoprolol vs. amlodipine</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" colspan="8" rowspan="1"><hr/></td></tr><tr><td colspan="8" align="left" rowspan="1"><italic>vs. diuretics</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Deary [<xref rid="B4" ref-type="bibr">4</xref>]</td><td align="left" rowspan="1" colspan="1">2002</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">bisoprolol vs. bendrofluazide</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx bendrofluazide better</td></tr><tr><td align="left" rowspan="1" colspan="1">Morgan [<xref rid="B5" ref-type="bibr">5</xref>]</td><td align="left" rowspan="1" colspan="1">2004</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">&#x000df;-blockers vs. diuretics</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx diuretics better</td></tr><tr><td align="left" colspan="8" rowspan="1"><hr/></td></tr><tr><td colspan="8" align="left" rowspan="1"><bold>CCBs</bold></td></tr><tr><td colspan="8" align="left" rowspan="1"><italic>vs. diuretics</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Asmar [<xref rid="B37" ref-type="bibr">37</xref>]</td><td align="left" rowspan="1" colspan="1">1993</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">felodipine vs. hydrochlorothiazide</td><td align="left" rowspan="1" colspan="1">cfPWV felodipine better</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Deary [<xref rid="B4" ref-type="bibr">4</xref>]</td><td align="left" rowspan="1" colspan="1">2002</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">amlodipine vs. bendrofluazide</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Morgan [<xref rid="B5" ref-type="bibr">5</xref>]</td><td align="left" rowspan="1" colspan="1">2004</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">CCBs vs. diuretics</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" colspan="8" rowspan="1"><hr/></td></tr><tr><td colspan="8" align="left" rowspan="1"><bold>Other</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Mahmud [<xref rid="B30" ref-type="bibr">30</xref>]</td><td align="left" rowspan="1" colspan="1">2002</td><td align="left" rowspan="1" colspan="1">SB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">captopril + valsartan vs. captopril vs. valsartan</td><td align="left" rowspan="1" colspan="1">cfPWV combination better</td><td align="left" rowspan="1" colspan="1">AIx combination better</td></tr><tr><td align="left" rowspan="1" colspan="1">Ferguson [<xref rid="B38" ref-type="bibr">38</xref>]</td><td align="left" rowspan="1" colspan="1">2008</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">fosinopril + hydrochlorothiazide vs. amlodipine vs. indapamide</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx combination better</td></tr></tbody></table><table-wrap-foot><fn><p>ACEIs = ACE inhibitors; AIx = augmentation index; AIx@HR75 = AIx corrected for heart rate of 75 beats/min; aPWV = aortic pulse wave velocity; AUC = area under the curve; CAD = coronary artery disease; cfPWV = carotid-femoral pulse wave velocity; DB = double-blinded; DM = diabetes mellitus; EH = essential hypertension; NS = not significantly different; SB = single-blinded.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Randomized actively-controlled parallel-group comparison studies</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th align="left" rowspan="1" colspan="1">First author</th><th align="left" rowspan="1" colspan="1">Year</th><th align="left" rowspan="1" colspan="1">Design</th><th align="left" rowspan="1" colspan="1">Subjects</th><th align="left" rowspan="1" colspan="1">Patients, n</th><th align="left" rowspan="1" colspan="1">Comparison(s)</th><th colspan="2" align="left" rowspan="1">Results<hr/></th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">arterial stiffness</th><th align="left" rowspan="1" colspan="1">wave reflections</th></tr></thead><tbody><tr><td colspan="8" align="left" rowspan="1"><bold>ACEIs</bold></td></tr><tr><td colspan="8" align="left" rowspan="1"><italic>vs. ARBs</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Rajzer [<xref rid="B39" ref-type="bibr">39</xref>]</td><td align="left" rowspan="1" colspan="1">2003</td><td align="left" rowspan="1" colspan="1">open</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">62</td><td align="left" rowspan="1" colspan="1">quinapril vs. losartan</td><td align="left" rowspan="1" colspan="1">cfPWV quinapril better</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Takami [<xref rid="B40" ref-type="bibr">40</xref>]</td><td align="left" rowspan="1" colspan="1">2003</td><td align="left" rowspan="1" colspan="1">SB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">temocapril vs. valsartan</td><td align="left" rowspan="1" colspan="1">baPWV valsartan better</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Ichihara [<xref rid="B16" ref-type="bibr">16</xref>]</td><td align="left" rowspan="1" colspan="1">2005</td><td align="left" rowspan="1" colspan="1">SB</td><td align="left" rowspan="1" colspan="1">hemodialysis patients</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">trandolapril vs. losartan</td><td align="left" rowspan="1" colspan="1">baPWV NS</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Anan [<xref rid="B41" ref-type="bibr">41</xref>]</td><td align="left" rowspan="1" colspan="1">2005</td><td align="left" rowspan="1" colspan="1">SB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">perindopril vs. valsartan</td><td align="left" rowspan="1" colspan="1">baPWV NS</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Rehman [<xref rid="B42" ref-type="bibr">42</xref>]</td><td align="left" rowspan="1" colspan="1">2007</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1">perindopril vs. losartan</td><td align="left" rowspan="1" colspan="1">cfPWV NS</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Li [<xref rid="B43" ref-type="bibr">43</xref>]</td><td align="left" rowspan="1" colspan="1">2009</td><td align="left" rowspan="1" colspan="1">SB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">68</td><td align="left" rowspan="1" colspan="1">perindopril vs. telmisartan</td><td align="left" rowspan="1" colspan="1">baPWV telmisartan better</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" colspan="8" rowspan="1"><hr/></td></tr><tr><td colspan="8" align="left" rowspan="1"><italic>vs. &#x000df;-blockers</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Kahonen [<xref rid="B14" ref-type="bibr">14</xref>]</td><td align="left" rowspan="1" colspan="1">1998</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">healthy volunteers</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">captopril vs. propranolol</td><td align="left" rowspan="1" colspan="1">aPWV NS</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Mackenzie [<xref rid="B44" ref-type="bibr">44</xref>]</td><td align="left" rowspan="1" colspan="1">2009</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">perindopril vs. atenolol</td><td align="left" rowspan="1" colspan="1">cfPWV NS</td><td align="left" rowspan="1" colspan="1">AIx perindopril better</td></tr><tr><td align="left" colspan="8" rowspan="1"><hr/></td></tr><tr><td colspan="8" align="left" rowspan="1"><italic>vs. CCBs</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">London [<xref rid="B45" ref-type="bibr">45</xref>]</td><td align="left" rowspan="1" colspan="1">1994</td><td align="left" rowspan="1" colspan="1">SB</td><td align="left" rowspan="1" colspan="1">ESRD</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">perindopril vs. nitrendipine</td><td align="left" rowspan="1" colspan="1">cfPWV NS</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Kahonen [<xref rid="B14" ref-type="bibr">14</xref>]</td><td align="left" rowspan="1" colspan="1">1998</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">healthy volunteers</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">captopril vs. verapamil</td><td align="left" rowspan="1" colspan="1">aPWV NS</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Rajzer [<xref rid="B39" ref-type="bibr">39</xref>]</td><td align="left" rowspan="1" colspan="1">2003</td><td align="left" rowspan="1" colspan="1">open</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">75</td><td align="left" rowspan="1" colspan="1">quinapril vs. amlodipine</td><td align="left" rowspan="1" colspan="1">cfPWV quinapril better</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Takami [<xref rid="B40" ref-type="bibr">40</xref>]</td><td align="left" rowspan="1" colspan="1">2003</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">temocapril vs. cilnidipine</td><td align="left" rowspan="1" colspan="1">baPWV NS</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">temocapril vs. nifedipine</td><td align="left" rowspan="1" colspan="1">baPWV temocapril better</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Morimoto [<xref rid="B46" ref-type="bibr">46</xref>]</td><td align="left" rowspan="1" colspan="1">2008</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">ARB + perindopril vs. ARB + amlodipine</td><td align="left" rowspan="1" colspan="1">baPWV NS</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Mackenzie [<xref rid="B44" ref-type="bibr">44</xref>]</td><td align="left" rowspan="1" colspan="1">2009</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1">perindopril vs. lercanidipine</td><td align="left" rowspan="1" colspan="1">cfPWV NS</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Li [<xref rid="B43" ref-type="bibr">43</xref>]</td><td align="left" rowspan="1" colspan="1">2009</td><td align="left" rowspan="1" colspan="1">SB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">68</td><td align="left" rowspan="1" colspan="1">perindopril vs. amlodipine</td><td align="left" rowspan="1" colspan="1">baPWV amlodipine better</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" colspan="8" rowspan="1"><hr/></td></tr><tr><td colspan="8" align="left" rowspan="1"><italic>vs. diuretics</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Breithaupt-Grogler [<xref rid="B47" ref-type="bibr">47</xref>]</td><td align="left" rowspan="1" colspan="1">1996</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">cilazapril vs. hydrochlorothiazide</td><td align="left" rowspan="1" colspan="1">cfPWV NS</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Jiang [<xref rid="B48" ref-type="bibr">48</xref>]</td><td align="left" rowspan="1" colspan="1">2005</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">101</td><td align="left" rowspan="1" colspan="1">enalapril vs. indapamide</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx enalapril better</td></tr><tr><td align="left" rowspan="1" colspan="1">Mackenzie [<xref rid="B44" ref-type="bibr">44</xref>]</td><td align="left" rowspan="1" colspan="1">2009</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">perindopril vs. bendrofluazide</td><td align="left" rowspan="1" colspan="1">cfPWV NS</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Kostka-Jeziorny [<xref rid="B49" ref-type="bibr">49</xref>]</td><td align="left" rowspan="1" colspan="1">2011</td><td align="left" rowspan="1" colspan="1">open</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">perindopril vs. hydrochlorothiazide</td><td align="left" rowspan="1" colspan="1">cfPWV NS</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" colspan="8" rowspan="1"><hr/></td></tr><tr><td colspan="8" align="left" rowspan="1"><bold>ARBs</bold></td></tr><tr><td colspan="8" align="left" rowspan="1"><italic>vs. &#x000df;-blockers</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Boutouyrie [<xref rid="B50" ref-type="bibr">50</xref>]</td><td align="left" rowspan="1" colspan="1">2010</td><td align="left" rowspan="1" colspan="1">open</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">331</td><td align="left" rowspan="1" colspan="1">amlodipine + valsartan vs. amlodipine + atenolol</td><td align="left" rowspan="1" colspan="1">cfPWV NS</td><td align="left" rowspan="1" colspan="1">AIx and AIx@HR75 valsartan better</td></tr><tr><td align="left" rowspan="1" colspan="1">Vitale [<xref rid="B51" ref-type="bibr">51</xref>]</td><td align="left" rowspan="1" colspan="1">2012</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">65</td><td align="left" rowspan="1" colspan="1">irbesartan vs. nebivolol</td><td align="left" rowspan="1" colspan="1">cfPWV NS</td><td align="left" rowspan="1" colspan="1">AIx irbesartan better; AIx@HR75 NS</td></tr><tr><td align="left" colspan="8" rowspan="1"><hr/></td></tr><tr><td colspan="8" align="left" rowspan="1"><italic>vs. CCBs</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Rajzer [<xref rid="B39" ref-type="bibr">39</xref>]</td><td align="left" rowspan="1" colspan="1">2003</td><td align="left" rowspan="1" colspan="1">open</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1">losartan vs. amlodipine</td><td align="left" rowspan="1" colspan="1">cfPWV NS</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Takami [<xref rid="B40" ref-type="bibr">40</xref>]</td><td align="left" rowspan="1" colspan="1">2003</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">valsartan vs. cilnidipine vs. nifedipine</td><td align="left" rowspan="1" colspan="1">baPWV valsartan better</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Munakata [<xref rid="B52" ref-type="bibr">52</xref>]</td><td align="left" rowspan="1" colspan="1">2004</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">valsartan vs. nifedipine</td><td align="left" rowspan="1" colspan="1">baPWV valsartan better</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Ichihara [<xref rid="B53" ref-type="bibr">53</xref>]</td><td align="left" rowspan="1" colspan="1">2006</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">valsartan vs. amlodipine</td><td align="left" rowspan="1" colspan="1">baPWV NS</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Morimoto [<xref rid="B54" ref-type="bibr">54</xref>]</td><td align="left" rowspan="1" colspan="1">2006</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">telmisartan vs. amlodipine</td><td align="left" rowspan="1" colspan="1">baPWV telmisartan better</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Kosch [<xref rid="B55" ref-type="bibr">55</xref>]</td><td align="left" rowspan="1" colspan="1">2008</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">valsartan vs. metoprolol</td><td align="left" rowspan="1" colspan="1">cfPWV NS</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Ishii [<xref rid="B56" ref-type="bibr">56</xref>]</td><td align="left" rowspan="1" colspan="1">2008</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">EH/DM</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">candesartan vs. CCBs</td><td align="left" rowspan="1" colspan="1">baPWV candesartan better</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Schneider [<xref rid="B57" ref-type="bibr">57</xref>]</td><td align="left" rowspan="1" colspan="1">2008</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">156</td><td align="left" rowspan="1" colspan="1">irbesartan vs. atenolol</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx irbesartan better</td></tr><tr><td align="left" rowspan="1" colspan="1">Li [<xref rid="B43" ref-type="bibr">43</xref>]</td><td align="left" rowspan="1" colspan="1">2009</td><td align="left" rowspan="1" colspan="1">SB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">68</td><td align="left" rowspan="1" colspan="1">telmisartan vs. amlodipine</td><td align="left" rowspan="1" colspan="1">baPWV telmisartan better</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Tomiyama [<xref rid="B58" ref-type="bibr">58</xref>]</td><td align="left" rowspan="1" colspan="1">2011</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">113</td><td align="left" rowspan="1" colspan="1">candesartan vs. amlodipine</td><td align="left" rowspan="1" colspan="1">baPWV candesartan better</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" colspan="8" rowspan="1"><hr/></td></tr><tr><td colspan="8" align="left" rowspan="1"><italic>vs. diuretics</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Klingbeil [<xref rid="B23" ref-type="bibr">23</xref>]</td><td align="left" rowspan="1" colspan="1">2002</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">valsartan vs. hydrochlorothiazide</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx valsartan better</td></tr><tr><td align="left" colspan="8" rowspan="1"><hr/></td></tr><tr><td colspan="8" align="left" rowspan="1"><bold>&#x003b2;-Blockers</bold></td></tr><tr><td colspan="8" align="left" rowspan="1"><italic>vs. CCBs</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Merli [<xref rid="B59" ref-type="bibr">59</xref>]</td><td align="left" rowspan="1" colspan="1">1993</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">metoprolol vs. isradipine</td><td align="left" rowspan="1" colspan="1">cfPWV isradipine better</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Kahonen [<xref rid="B14" ref-type="bibr">14</xref>]</td><td align="left" rowspan="1" colspan="1">1998</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">healthy</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">propranolol vs. verapamil volunteers</td><td align="left" rowspan="1" colspan="1">cfPWV propranolol better</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Ylitalo [<xref rid="B26" ref-type="bibr">26</xref>]</td><td align="left" rowspan="1" colspan="1">2005</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">healthy volunteers</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">bisoprolol vs. nisoldipine</td><td align="left" rowspan="1" colspan="1">cfPWV NS</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Mackenzie [<xref rid="B44" ref-type="bibr">44</xref>]</td><td align="left" rowspan="1" colspan="1">2009</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">atenolol vs. lercanidipine</td><td align="left" rowspan="1" colspan="1">cfPWV NS</td><td align="left" rowspan="1" colspan="1">AIx lercanidipine better</td></tr><tr><td align="left" colspan="8" rowspan="1"><hr/></td></tr><tr><td colspan="8" align="left" rowspan="1"><italic>vs. diuretics</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Mackenzie [<xref rid="B44" ref-type="bibr">44</xref>]</td><td align="left" rowspan="1" colspan="1">2009</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">atenolol vs. bendrofluazide</td><td align="left" rowspan="1" colspan="1">cfPWV NS</td><td align="left" rowspan="1" colspan="1">AIx bendrofluazide better</td></tr><tr><td align="left" colspan="8" rowspan="1"><hr/></td></tr><tr><td colspan="8" align="left" rowspan="1"><bold>CCBs</bold></td></tr><tr><td colspan="8" align="left" rowspan="1"><italic>vs. CCBs</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Takami [<xref rid="B40" ref-type="bibr">40</xref>]</td><td align="left" rowspan="1" colspan="1">2003</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">cilnidipine vs. nifedipine</td><td align="left" rowspan="1" colspan="1">baPWV cilnidipine better</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" colspan="8" rowspan="1"><hr/></td></tr><tr><td colspan="8" align="left" rowspan="1"><italic>vs. diuretics</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">White [<xref rid="B60" ref-type="bibr">60</xref>]</td><td align="left" rowspan="1" colspan="1">2003</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">139</td><td align="left" rowspan="1" colspan="1">amlodipine vs. eplerenone</td><td align="left" rowspan="1" colspan="1">cfPWV NS</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Williams [<xref rid="B61" ref-type="bibr">61</xref>]</td><td align="left" rowspan="1" colspan="1">2006</td><td align="left" rowspan="1" colspan="1">open</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">2,073</td><td align="left" rowspan="1" colspan="1">amlodipine vs. atenolol</td><td align="left" rowspan="1" colspan="1">cfPWV NS (n = 114)</td><td align="left" rowspan="1" colspan="1">AIx amlodipine better</td></tr><tr><td align="left" rowspan="1" colspan="1">Kaneshiro [<xref rid="B62" ref-type="bibr">62</xref>]</td><td align="left" rowspan="1" colspan="1">2009</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">CKD</td><td align="left" rowspan="1" colspan="1">68</td><td align="left" rowspan="1" colspan="1">valsartan + amlodipine vs. valsartan + thiazide</td><td align="left" rowspan="1" colspan="1">baPWV NS</td><td align="left" rowspan="1" colspan="1">not measured</td></tr><tr><td align="left" rowspan="1" colspan="1">Mackenzie [<xref rid="B44" ref-type="bibr">44</xref>]</td><td align="left" rowspan="1" colspan="1">2009</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">lercanidipine vs. bendrofluazide</td><td align="left" rowspan="1" colspan="1">cfPWV NS</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Doi [<xref rid="B63" ref-type="bibr">63</xref>]</td><td align="left" rowspan="1" colspan="1">2010</td><td align="left" rowspan="1" colspan="1">open</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">37</td><td align="left" rowspan="1" colspan="1">azelnidipine vs. trichlormethiazide</td><td align="left" rowspan="1" colspan="1">not measured</td><td align="left" rowspan="1" colspan="1">AIx and AIx@HR75 azelnidipine better</td></tr><tr><td align="left" rowspan="1" colspan="1">Matsui [<xref rid="B64" ref-type="bibr">64</xref>]</td><td align="left" rowspan="1" colspan="1">2011</td><td align="left" rowspan="1" colspan="1">open</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">207</td><td align="left" rowspan="1" colspan="1">azelnidipine vs. hydrochlorothiazide</td><td align="left" rowspan="1" colspan="1">cfPWV azelnidipine better</td><td align="left" rowspan="1" colspan="1">AIx NS</td></tr><tr><td align="left" colspan="8" rowspan="1"><hr/></td></tr><tr><td colspan="8" align="left" rowspan="1"><bold>Other</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Asmar [<xref rid="B65" ref-type="bibr">65</xref>]</td><td align="left" rowspan="1" colspan="1">2001</td><td align="left" rowspan="1" colspan="1">DB</td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">406</td><td align="left" rowspan="1" colspan="1">perindopril + indapamide vs. atenolol</td><td align="left" rowspan="1" colspan="1">cfPWV NS</td><td align="left" rowspan="1" colspan="1">AIx combination better</td></tr><tr><td align="left" rowspan="1" colspan="1">Anan [<xref rid="B41" ref-type="bibr">41</xref>]</td><td align="left" rowspan="1" colspan="1">2005</td><td align="left" rowspan="1" colspan="1"><sup>&#x02013;</sup></td><td align="left" rowspan="1" colspan="1">EH</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">perindopril + valsartan vs. perindopril vs. valsartan</td><td align="left" rowspan="1" colspan="1">baPWV combination better</td><td align="left" rowspan="1" colspan="1">not measured</td></tr></tbody></table><table-wrap-foot><p>ACEIs = ACE inhibitors; AIx = augmentation index; AIx@HR75 = AIx corrected for heart rate of 75 beats/min; aPWV = aortic pulse wave velocity; baPWV = brachial-ankle pulse wave velocity; cfPWV = carotid-femoral pulse wave velocity; CKD = chronic kidney disease; DB = double-blinded; DM = diabetes mellitus; EH = essential hypertension; ESRD = end-stage renal dysfunction; NS = not significantly different; SB = single-blinded.</p></table-wrap-foot></table-wrap></floats-group></article>